



## Drug Evaluation

Reviews, featuring  
therapeutics Articles

c 34-030, Birkenhead.

Drugs 28: 485-518 (1984)  
0012-6667/84/1200-0485/\$17.00/0  
© ADIS Press Limited  
All rights reserved.

### Budesonide

A Preliminary Review of its Pharmacodynamic Properties and  
Therapeutic Efficacy in Asthma and Rhinitis

S.P. Cusoid and R.C. Heel

ADIS Drug Information Services, Auckland

Id, Eugene M. Sorlin

D.W. Beaven, R.F.A.  
B. Jellat, P. Kincaid  
Powell, M.J. Rend  
ood, R. Zaccari

Donato: S.K. Carter,  
W. Golubev, San  
tario: L.E. Hollister,  
London; A. Klepper,  
A. Marble, Boston,  
cDowell, New York;  
ngham: J.C. Patria  
a, Edinburgh; S.H.  
weastie upon Tyne;  
ells, Birmingham;  
n. ilcox, London

8943, USA, Air freight

1984, USA, Air freight

BEST AVAILABLE COPY

Various sections of the manuscript reviewed by: G.M. Cochrane, Department of Thoracic Medicine, Guy's and New Cross Hospitals, London, England; R. Boff, Department of Pulmonary Diseases, Århus Kommunehospital, Århus, Denmark; J.M. Henriksen, Department of Pediatrics, Århus University Hospital, Århus, Denmark; M.T. Jackson, Laboratory of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA; A.B. Key, Department of Allergy and Clinical Immunology, The Cardiothoracic Institute, London, England; J. Marston-Smith, Penryn, Fishguard, Wales; H. Møgel, University ENT Department, Rigshospitalet, Copenhagen, Denmark; J.J. Rasmussen, Pulmonary Disease Section, Veterans Administration Medical Center, Phoenix, Arizona, USA; J.H. Toogood, Allergy Clinic, Victoria Hospital, London, Ontario, Canada; J.O. Warner, Brompton Hospital, London, England; M.H. Williams, Pulmonary Division, Department of Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx Municipal Hospital Center, New York, USA; J.O. Wilson, Department of Immunobiology, School of Medicine, University of Auckland, New Zealand.

### Contents

Summary .....	486
1. Pharmacodynamic Studies .....	489
1.1 Topical and Systemic Glucocorticoid Activity .....	489
1.2 Effect on Haematological Parameters .....	491
1.3 Effect on Adrenal Function .....	491
1.4 Effect on Antigen-Induced Reactions .....	493
1.4.1 Effect on Bronchial Allergen Challenge .....	493
1.4.2 Effect on Nasal Allergen Challenge .....	493
1.4.3 Antinaphylactic Activity .....	494
1.5 Effect on Bronchial and Nasal Mucosa .....	495
1.6 Acute Dose-Response Studies .....	495
2. Pharmacokinetic Studies .....	496
2.1 Absorption .....	497
2.2 Distribution .....	497
2.3 Elimination .....	497
2.3.1 Metabolism .....	498
2.3.2 Excretion .....	498
2.3.3 Half-Life .....	499
3. Therapeutic Trials in Asthma .....	499
3.1 Short Term Studies in Asthma .....	499
3.1.1 Inhaled Budesonide Compared with Oral Steroids .....	500

3.1.2 Budesonide in Asthmatic Children	501
3.1.3 Twice Daily vs Four Times Daily Administration	501
3.1.4 Effect of Spacer Devices	502
3.2 Long Term Studies in Asthma	502
3.3 Budesonide Compared with Other Inhaled Corticosteroids	504
4. Therapeutic Trials in Rhinitis	505
4.1 Comparisons with Placebo in Seasonal Allergic Rhinitis	505
4.2 Trials in Perennial Rhinitis	508
4.2.1 Placebo-Controlled Studies	508
4.2.2 Open Studies	508
4.3 Budesonide Compared with Other Drugs	509
5. Treatment of Nasal Polyposis	511
6. Side Effects	511
6.1 Inhaled Budesonide	511
6.1.1 Candidiasis, Dysphonia and Sore Throat	511
6.1.2 Systemic Corticosteroid Withdrawal Effects	512
6.1.3 Adrenal Suppression	512
6.1.4 Laboratory Data and Miscellaneous Side Effects	512
6.2 Intranasal Budesonide	513
7. Dosage and Administration	513
7.1 Asthma	513
7.2 Rhinitis	513
8. The Place of Budesonide in Therapy	514

## Summary

**Synopsis:** Budesonide<sup>1</sup> is a non-halogenated glucocorticosteroid which has been shown to possess a high ratio of topical to systemic activity compared with a number of reference corticosteroids such as beclomethasone dipropionate, flunisolide, and triamcinolone acetonide. It appears to undergo extensive first-pass metabolism to metabolites of minimal activity which accounts for the low level of systemic activity.

The majority of therapeutic trials in asthma have been of short term duration and have demonstrated that conventional doses of inhaled budesonide (200 to 800 µg/day) and beclomethasone dipropionate (400 to 800 µg/day) are of similar efficacy in both adults and children with moderate to severe asthma. Other studies have compared high doses of inhaled budesonide (400 to 3200 µg/day in 4 divided doses) with both alternate day (7.5 to 60mg) and daily (7.5 to 40mg) oral prednisone in patients with severe or unstable asthma. In the small number of such trials to date, inhaled budesonide was superior to prednisone with respect to the level of asthma control and the lesser influence on adrenal function. Long term open studies have similarly shown that inhaled budesonide can be gradually substituted for oral prednisone in steroid-dependent patients, often with a concomitant improvement in pulmonary function and asthma control.

Intranasal budesonide (200 to 400 µg/day) relieves nasal symptoms in patients with seasonal allergic, perennial allergic and vasomotor rhinitis. In comparative studies in patients with seasonal rhinitis it has been shown to be of similar efficacy as intranasal flunisolide and intranasal beclomethasone dipropionate and superior to intranasal sodium cromoglycate (cromolyn sodium) and the antihistamine dexchlorpheniramine.

Following inhalation, the most commonly reported side effects have been candidiasis, dysphonia and sore throat, while after intranasal administration the most frequent adverse reactions have been nasal stinging, throat irritation, dry nose and slight nasal bleeding. At usual dosages, both formulations of budesonide appear to have little or no effect on adrenal function.

<sup>1</sup> 'Pulmicort', 'Rhinocort', 'Spirocort' (Astra)

501
501
502
502
503
503
508
508
508
509
511
511
511
512
512
512
513
513
513
513
514

which has been shown  
a number of reference  
d triamcinolone ace-  
tobolites of minimal

m duration and have  
800 µg/day) and be-  
y in both adults and  
red high doses of in-  
alternate day (7.5 to  
or unstable asthma.  
uperior to prednisone  
on adrenal function.  
ide can be gradually  
with a concomitant

ms in patients with  
operative studies in  
ficacy as intranasal  
o intranasal sodium  
streamine.  
re been candidiasis.  
ost frequent adverse  
ight nasal bleeding.  
little or no effect on

Thus, at this stage in its development budesonide has been shown to offer an effective alternative to oral or other inhaled corticosteroids in the management of asthma and rhinitis. However, its relative efficacy and tolerability during long term use, compared with beclomethasone dipropionate, remains to be clarified.

**Pharmacodynamic Studies:** In animals budesonide has a high ratio of topical to systemic activity compared with reference corticosteroids such as beclomethasone dipropionate, flunisolide and triamcinolone acetonide. In man, budesonide was shown to have 1.6 to 3 times greater local anti-inflammatory activity using a skin vasoconstriction assay, and between 2 and 4 times less systemic activity than beclomethasone dipropionate. The reduction in systemic potency in healthy volunteers should augur well for the clinical usefulness of budesonide, and trials in patients with asthma have not revealed any significant differences between conventional doses of budesonide and beclomethasone dipropionate. In practice, usual doses of inhaled or intranasal budesonide have caused only minimal changes in hypothalamic-pituitary-adrenal (HPA) function, although a dose-response relationship with plasma cortisol concentrations has been documented. When inhaled therapy was substituted for oral prednisolone there was a gradual increase in plasma cortisol concentrations, highlighting the lower adrenal suppressive activity of budesonide compared with oral steroid.

Even after single doses, inhaled budesonide produced a rapid improvement in pulmonary function in patients with asthma, characterised by a dose-response relationship with peak expiratory flow rate. A divided daily regimen gave a more pronounced and longlasting increase in lung function at a reduced total daily dosage compared with a single daily dose.

The mechanism of action of budesonide, like that for other glucocorticoids, remains obscure. However, it has been noted that as long as pretreatment was sufficiently long, inhaled budesonide inhibited both the immediate and late reactions provoked by bronchial allergen challenge. Similarly, intranasal budesonide inhibited the type I-mediated immediate nasal reaction and this may be related to suppression of histamine release in nasal biopsy samples *in vitro*.

Following intranasal administration of budesonide for up to 1 year in patients with rhinitis, no adverse morphological changes in the nasal mucosa occurred. However, no studies evaluating the histological characteristics of the bronchial mucosa after inhaled budesonide have been reported.

**Pharmacokinetic Studies:** In man, peak plasma concentrations of unchanged budesonide occurred within 1 hour of inhalation and approximately 3 hours after oral ingestion, thus reflecting the rapid rate of absorption from the lung. Systemic bioavailability was calculated to be 10.7% after oral administration, with evidence of extensive first-pass metabolism.

The volume of distribution of budesonide is comparatively large (301L), which is indicative of wide tissue distribution. Budesonide has been shown to be extensively bound to plasma proteins (86.3%) with negligible binding to transcortin. The relatively short elimination half-life (approximately 2 hours) and high plasma clearance (63.7 L/hour) highlight the rapid systemic elimination of budesonide. *In vitro* studies have corroborated the involvement of the liver in the rapid biotransformation of budesonide; 2 major metabolites with minimal activity have been isolated and identified. Only trace amounts of budesonide are excreted unchanged in the urine.

**Therapeutic Trials:** The majority of clinical trials with inhaled budesonide have been crossover studies designed to evaluate the effectiveness of different dosage regimens, or its comparative efficacy with that of inhaled beclomethasone dipropionate. Most were of short duration (2 to 4 weeks) and, when peak expiratory flow rate was measured, demonstrated a dose-response relationship over a wide range of inhaled dosages (100 to 1600 µg/day in divided doses) in patients with moderately severe and severe (steroid

dependent) asthma. The dose-response relationship was maintained whether budesonide was administered twice or 4 times daily.

In short term comparative trials inhaled budesonide (400 to 3200 µg/day in 4 divided doses) was found to be superior to alternate-day oral prednisone (7.5 to 60mg) in patients with moderate to severe asthma, and was able to produce as effective control of unstable asthma as daily oral prednisone (7.5 to 40mg once daily). In this latter study, at doses producing equivalent control of the asthmatic condition, inhaled budesonide had significantly less effect on adrenal function. In other comparative trials, inhaled budesonide (200 to 800 µg/day) was of approximately equal efficacy as inhaled beclomethasone dipropionate (400 to 800 µg/day) in both adults and children with asthma. In long term open trials gradual substitution of inhaled budesonide for oral steroid has often resulted in an improvement in pulmonary function and asthma control. Oral steroid dosage was usually markedly decreased during budesonide administration, and 1600 µg/day of inhaled budesonide reduced mean oral prednisone usage by half.

Intranasal budesonide has been used in the treatment of seasonal allergic, perennial allergic and vasomotor rhinitis. In seasonal rhinitis doses of 200 to 400 µg/day were significantly better than placebo in relieving nasal symptoms and reducing the need for supplemental antiallergy medication, but had no effect on eye symptoms. In patients with seasonal allergic rhinitis, intranasal budesonide was as effective as intranasal beclomethasone dipropionate and intranasal flunisolide, and significantly superior to both intranasal sodium cromoglycate and the oral antihistamine dexchlorpheniramine. Short term comparisons in patients with perennial rhinitis, with or without an allergic component, have shown budesonide to be significantly better than placebo in relieving nasal symptoms when doses of 200 to 400 µg/day were administered. In long term open trials in patients with perennial rhinitis, intranasal budesonide (200 to 400 µg/day) has consistently produced a significant reduction in all nasal symptoms with a low incidence of mild and transient side effects.

In patients with nasal polyposis, budesonide was significantly more effective than placebo in reducing total symptom scores and increasing nasal peak flow rates, while rhinoscopy revealed a distinct decrease in nasal congestion, a decrease in polyp size, and a significant reduction in the number of polyps. However, only 10 patients received the active drug in this study and a well-designed trial in a greater number of patients is required to confirm the usefulness of intranasal budesonide in this condition.

**Side Effects:** Generally, budesonide has been well tolerated and few trials have reported adverse reactions associated with treatment. However, the majority of these studies have been of short term duration (2 to 4 weeks). Longer term trials in greater numbers of patients are required to fully evaluate the tolerability of budesonide.

Using the inhaled preparation, the most commonly reported side effects have been oropharyngeal candidiasis, hoarseness and sore throat, as is also the case with other inhaled corticosteroids. The reported incidence of candidiasis varied widely among studies, but was reduced by using a spacer device or by reverting to a less frequent dosing regimen. Gradual substitution of inhaled budesonide for oral prednisolone resulted in a number of side effects such as hoarseness, sore throat, arthralgia, myalgia, exacerbation of eczema and pulmonary eosinophilia and sarcoidosis, which can all be explained in terms of a local reaction or are indicative of systemic corticosteroid withdrawal. Administration of inhaled budesonide, up to 800 µg/day, appears to have a minimal effect on adrenal function as assessed by basal plasma cortisol concentrations and their increase after tetracosactrin stimulation. Nevertheless, during substitution of inhaled budesonide for oral corticosteroid, recovery of hypothalamic-pituitary-adrenal integrity can take up to 12 months after long term oral steroid therapy, and it is essential to take special care during this period.

Intranasal budesonide has been well tolerated, and in both long and short term trials in patients with rhinitis the most common side effects have been local reactions such as nasal stinging, throat irritation, dry nose and nasal bleeding. In comparative studies,

1. P

Bec  
steroid  
hydron  
[fig. 1]  
designa  
et al., 1  
al., 197  
similar  
recent  
to 3 d  
has a c  
useful  
in the  
cepted  
mains  
inflam  
import  
system  
budec  
might  
regard

L. I  
Ac.

U  
estim  
senid  
steroi

whether budesonide

100 µg/day in 4 divided doses (25 mg) in patients with poor control of unstable asthma. In the latter study, at doses of 100 µg/day, inhaled budesonide was as effective as inhaled beclomethasone dipropionate. In long term studies, inhaled budesonide has often resulted in a lower steroid dosage than inhaled beclomethasone dipropionate. In a study of 1600 µg/day of in-

haled allergic, perennial rhinitis, doses of 400 µg/day were effective in reducing the need for symptomatic treatment. In patients with allergic rhinitis, inhaled budesonide was superior to both chlorpheniramine and cromoglycate. Short term studies in relieving nasal symptoms in long term open trials (100 µg/day) has shown a low incidence of

more effective than placebo at low rates, while side effects in polyp size, and patients received the number of patients in condition.

In few trials have the majority of these studies been in greater numbers.

Side effects have been reported in a case with other inhaled steroids. In a study among studies, less frequent dosing of budesonide resulted in a decrease in nasal symptoms, all of which can be explained in withdrawal. Administration of a minimal effect on nasal symptoms and their increase in inhaled budesonide integrity can take up to 1 to take special care

and short term trials in nasal reactions such as comparative studies.

intranasal budesonide has produced fewer adverse effects than the antihistamine dexchlorpheniramine, significantly less nasal irritation than flunisolide, and equivalent incidences of minor transient reactions as intranasal beclomethasone dipropionate and intranasal sodium cromoglycate. No evidence of adrenal suppression has been reported with this formulation.

**Dosage and Administration:** The inhaled dose of budesonide for the treatment of asthma in adults should be individualised. The recommended initial dose is 400 to 1600 µg/day divided into 2 or 4 administrations. The maintenance dose is usually 200 to 400 µg/day - using the lowest dose that leaves the patient symptom free. In children with asthma the recommended dose is 200 to 400 µg/day, divided into 2 or 4 administrations.

In the treatment of rhinitis the recommended dosage is 100 µg (2 actuations of 50 µg each) into each nostril morning and evening (400 µg/day). This dosage can be halved once a good response has been achieved.

### 1. Pharmacodynamic Studies

Budesonide is a non-halogenated glucocorticosteroid which is structurally related to 16α-hydroxyprednisolone (Thälén and Brattsand, 1979) [fig. 1]. The drug is a 1 : 1 mixture of 2 epimers, designated 22R and 22S (Aherne et al., 1982; Roth et al., 1980; Thälén and Brattsand, 1979; Wikby et al., 1978), which were initially considered to have similar pharmacological activity. However, more recent evidence suggests that the 22R epimer is 2 to 3 times more potent than the 22S epimer and has a different pharmacokinetic profile. The clinical usefulness of inhaled and intranasal corticosteroids in the treatment of asthma and rhinitis is well accepted but their exact mechanism of action remains to be established. A high ratio of local anti-inflammatory to systemic activity appears to be an important indicator relating therapeutic efficacy to systemic tolerability, and the increased ratio for budesonide compared with other glucocorticoids might be expected to offer an advantage in this regard.

#### 1.1 Topical and Systemic Glucocorticoid Activity

Using the human skin vasoconstriction assay to estimate local anti-inflammatory activity, budesonide was more potent than the 5 other corticosteroids investigated (Johansson et al., 1982c) [fig.

2]. Employing the same test, budesonide has been shown to be as active as betamethasone dipropionate and more potent than betamethasone valerate, desonide, flunisolide, hydrocortisone butyrate and the acetanilides of fluocinolone, prednisolone and triamcinolone (Brattsand et al., 1982c,d; Gruvstad and Bengtsson, 1980; Johansson et al., 1982a,b). A comparison between budesonide and its 2 epimers indicated an order of topical activity of 22R > budesonide > 22S, with the 22R epimer approximately twice as potent as the 22S epimer (Brattsand et al., 1982c). Compared with beclomethasone dipropionate, budesonide has been shown to be approximately 1.6 to 3 times more active when applied topically (Johansson et al., 1982b,c).

The systemic glucocorticoid activity of budesonide, as determined by changes in plasma cortisol and total or differential white blood cell count in healthy volunteers, was 2 to 4 times less than that of beclomethasone dipropionate following oral administration, and it was also significantly less active after inhalation - although the disparity between the 2 drugs was less pronounced (Johansson et al., 1982c; Löfdahl et al., 1984) [fig. 3]. Following a single intravenous infusion of <sup>3</sup>H-budesonide 500 µg to 6 healthy male volunteers, total white blood cell count and lymphocyte count were transiently decreased, while the neutrophil count was increased after 4 hours (Ryrfeldt et al., 1984).

During the 8-hour study, the eosinophil count




Fig. 1. Structural formulae of 16 $\alpha$ -hydroxyprednisolone and budesonide in its 2 epimeric forms.

was reduced from 135 to 111/mm<sup>3</sup> after placebo and from 246 to 77/mm<sup>3</sup> after budesonide, but there were no statistically significant differences between the 2 groups. In contrast, plasma cortisol concentrations were slightly but significantly ( $p < 0.05$ ) suppressed 4 and 8 hours after budesonide administration compared with placebo values. In a comparison with oral prednisolone, the systemic potency (as assessed by depression of plasma cortisol) of 1.6mg of inhaled budesonide was equiv-

alent to 5mg of oral steroid, while 3.2mg of inhaled budesonide was approximately 2 times more potent than 5mg of oral prednisolone (Johansson et al., 1982b).

Animal studies confirm the increased ratio of topical to systemic activity of budesonide compared with a number of glucocorticoids such as beclomethasone dipropionate, flunisolide, flucinolone acetonide, and triamcinolone acetonide (Brattsand et al., 1982b,c,d; Thalén and Brattsand, 1979; Thalén et al., 1984). Using a recently developed model assessing local anti-inflammatory activity in the lung, budesonide instilled intratracheally or given by inhalation counteracted the pathophysiological changes (bronchial and interstitial infiltration of eosinophils and mononuclear cells) associated with the intratracheal administration of 'Sephadex' beads (Brattsand et al., 1983). Furthermore, local administration of budesonide produced a time-dependent inhibition of bradykin-induced inflammation in hamster cheek pouches (Svensjö and Roempke, 1984). In addition, budesonide and its 2 epimers have been shown to have




Fig. 2. Relative topical potency (area under the time-effect curve) of various glucocorticoids using the human skin vasoconstriction assay in 12 healthy volunteers (after Johansson et al., 1982c).

a high affinity for skeletal muscle and topical glucocorticoids (Johansson et al., 1984).

## 1.2 Effect on

Systemic prednisolone, blood neutrophils, eosinophils, hours of intravenous volunteers (Saavedra) effects have generally, normal with lymphopenia has administration of prednisolone patients (C).

In healthy subjects (2200ug) of inhaled budesonide dipropionate lymphocytes and number of neutrophils (the number of neutrophils) (1982c). The 2 doses (1 and 3mg), and inhaled budesonide dipropionate had a significant white cell response.

In contrast to the results of the study with aerosol for 4 weeks did not show any haematological changes. Similarly, an equal dose of budesonide dipropionate 100ug majority of patients was a tendency to a decrease in white cell count and a decrease in eosinophil count ( $p < 0.05$ ) in other studies in patients that neither inhaled nor oral prednisolone significantly affected the white cell count compared with placebo. Budesonide dipropionate 800ug prednisolone (15mg) did not have a steroid-dependent pa-

1 ratio of  
ide com-  
uch as be-  
fluocino-  
acetonide  
Brattsand,  
ntly devel-  
natory ac-  
l intratra-  
tracted the  
and inter-  
nonuclear  
dministrat-  
al., 1983).  
udesonide  
f bradykin-  
k pouches  
tion, budo-  
wn to have

a high affinity for the glucocorticoid receptor in rat skeletal muscle and this closely correlated with high topical glucocorticoid activity *in vivo* (Dahlberg et al., 1984).

### 1.2 Effect on Haematological Parameters

Systemic prednisone produces an increase in blood neutrophils and a decrease in blood basophils, eosinophils and lymphocytes within 4 to 8 hours of intravenous administration to healthy volunteers (Saavedra-Delgado et al., 1980). These effects have generally returned to, or are returning to, normal within 24 hours, and a similar transient lymphopenia has been noted following oral administration of prednisone to steroid-dependent asthmatic patients (Chiang et al., 1980).

In healthy subjects, single doses (200, 300 and 3200 µg) of inhaled budesonide and beclomethasone dipropionate decreased the number of lymphocytes and eosinophils and increased the number of neutrophils, without significantly affecting the number of monocytes (Johansson et al., 1982c). The 2 drugs were also given orally (2, 4 and 8 mg), and in both studies beclomethasone dipropionate had a significantly greater effect on the white cell response than did budesonide.

In contrast to these findings in volunteers, treatment with aerosol budesonide (200 µg twice daily) for 4 weeks did not significantly alter any of the haematological parameters measured in patients with chronic asthma (Willey et al., 1982). Similarly, an equal daily dose of beclomethasone dipropionate 100 µg 4 times a day did not affect the majority of parameters measured, although there was a tendency ( $p > 0.05 < 0.1$ ) to increase total white cell count and a small but significant reduction ( $p < 0.05$ ) in the number of neutrophils. Further studies in patients with asthma have shown that neither inhaled budesonide 400 to 3200 µg/day nor oral prednisone 7.5 to 60 mg on alternate days significantly altered the total blood eosinophil count compared with a baseline of beclomethasone dipropionate 500 µg/day alone or combined with prednisone (15 mg on alternate mornings) in steroid-dependent patients (unpublished data on file).




Fig. 2. Plasma cortisol (area under the curve) in healthy subjects after oral administration ( $n = 8$ ) and inhalation ( $n = 12$ ) of budesonide  $\square$  and beclomethasone dipropionate  $\blacksquare$  (after Johansson et al., 1992c).

Astra). However, a dose-dependent reduction in total blood eosinophils in patients with asthma was reported by Toegood et al. (1982b), although significant suppression was only observed when inhaled doses of budesonide were relatively high - 300 and 1600 µg/day in patients dependent and not dependent upon oral prednisone, respectively.

### 1.3 Effect on Adrenal Function

Resting early morning plasma cortisol concentrations, and those after tetracosactrin (synthetic ACTH) stimulation, provide useful information concerning the state of the hypothalamic-pituitary-adrenal (HPA) axis in asthmatic patients (Webb,

time-effect curve)  
in vasoconstriction  
son et al., 1982c).

1983). Significant reductions in plasma cortisol have seldom been observed using usual inhaled doses of beclomethasone dipropionate and betamethasone valerate (British Thoracic and Tuberculosis Association, 1975), flunisolide (Spangler et al., 1979) or triamcinolone acetonide (Bernstein et al., 1982). Of the inhaled corticoids, beclomethasone dipropionate has been the most extensively studied, and in 2 recent reviews (Brogden, 1983a; Brogden et al., 1984) daily doses of 400 to 2000 µg have been shown to cause some adrenal suppression in adult patients. In the majority of trials there has been a general improvement in adrenal function following the substitution of inhaled beclomethasone dipropionate for oral steroids, especially when oral treatment was on a once daily schedule. Recently, however, a less marked or no improvement has been observed following change-over from alternate-day oral steroids to inhaled beclomethasone dipropionate (Toogood, 1979; Wyatt et al., 1978).

As noted previously (section 1.1), budesonide administered orally and by inhalation was significantly less potent than equal doses of beclomethasone dipropionate in lowering plasma cortisol concentrations in healthy subjects (fig. 3). Greatly increased inhaled doses of budesonide (2400, 4800 and 7200 µg/day) and beclomethasone dipropionate (1500, 3000 and 4500 µg/day) both produced a dose-dependent decrease in morning serum cortisol concentrations in 12 healthy volunteers (Löfdahl et al., 1984). The dose-response curves ran parallel, and the results indicate that inhaled budesonide, at these high doses, possesses only 60% of the relative systemic activity of inhaled beclomethasone dipropionate. In patients with asthma, however, little or no adrenal suppression was noted with usual dosages of the 2 steroids (Ejörkander et al., 1982; Willey et al., 1982), and at high dosages both budesonide (1600 µg/day) and beclomethasone dipropionate (1500 µg/day) produced similar reductions of morning plasma cortisol (Ebdon and Davies, 1984). In these studies, neither drug affected the cortisol response to tetracosactrin stimulation. Substitution of inhaled budesonide (up to a mean of 1050 µg/day) for oral prednisolone in 30

steroid-dependent severely asthmatic patients over a period of 1 year induced a concomitant increase in plasma cortisol concentrations; this highlights the lower adrenal suppressive action of budesonide compared with oral prednisolone (Rosenhall et al., 1982b).

In a short term trial (2-week crossover), inhaled budesonide dosages of 400, 800 and 1600 µg/day were compared in 34 chronic asthmatics and a dose-dependent decrease in serum cortisol was observed (Toogood et al., 1982b). The reduction in serum cortisol was significantly different from baseline values at doses of 800 and 1600 µg/day in prednisone-dependent patients but only at a daily dosage of 1600 µg in patients not dependent on prednisone. It was also noted that morning-only treatment with high doses of budesonide tended to conserve hypothalamic-pituitary-adrenal (HPA) responsiveness but at the cost of a slight reduction in efficacy. In a similar study, a significant decrease in serum cortisol was only revealed at a daily budesonide dose of 3200 µg in prednisone users and no significant suppression of serum cortisol was documented for non-prednisone users at daily budesonide doses of 400 to 1600 µg (unpublished data on file, Astra).

The cortisol response to tetracosactrin stimulation in 7 asthmatic children was normal after 4 weeks' treatment with aerosol budesonide 400 µg/day (Henriksen and Dahl, 1983). Similarly, in 27 children with severe asthma requiring inhaled steroid therapy, neither budesonide (400 µg/day) nor beclomethasone dipropionate (400 µg/day) significantly altered basal cortisol concentrations or the response to tetracosactrin stimulation after 4 weeks' therapy (Field et al., 1982). More recently, 24-hour urinary cortisol excretion was not significantly changed in 12 asthmatic children treated with inhaled budesonide (400 µg/day with a spacer) for 3 weeks (Henriksen, 1984).

Intranasal budesonide 50 to 800 µg/day, used in the treatment of perennial or seasonal rhinitis for periods of 2 weeks to 1 year (section 4), did not suppress adrenal function as indicated by a lack of change in serum cortisol (Balle et al., 1980; Lindqvist et al., 1982, 1983; Malm et al., 1981;

Norman et al., 1983). The response to tetracosactrin stimulation was normal (1983; Field et al., 1984).

#### 1.4 Efficacy

Many studies have shown that budesonide is effective in the treatment of asthma, whether the allergen is inhaled or not. The mechanism of action is not clear, but it may be due to a direct effect on the inflammatory response.

#### 1.4.1 Efficacy

Early studies and studies in children have shown that budesonide is effective in the treatment of asthma, whether the allergen is inhaled or not. The mechanism of action is not clear, but it may be due to a direct effect on the inflammatory response.

The efficacy of budesonide in the treatment of asthma has been evaluated in a number of clinical studies. In a study by Dahl and colleagues (1983), budesonide was compared with placebo in the treatment of asthma. The results showed that budesonide was more effective than placebo in reducing the number of attacks and the need for oral steroids. In another study by Field et al. (1982), budesonide was compared with beclomethasone dipropionate in the treatment of asthma. The results showed that budesonide was as effective as beclomethasone dipropionate in reducing the number of attacks and the need for oral steroids.



Norman et al., 1984; Steensen and Lindqvist, 1981), the response of plasma cortisol to tetracosactrin stimulation (Balle, 1982; Lindqvist et al., 1982, 1983; Pipkorn and Berge, 1983), or in the excretion of urinary 17-hydroxycorticosteroids (Norman et al., 1984).

#### 1.4 Effect on Antigen-Induced Reactions

Many factors relating to the pathogenesis of asthma can be explained in terms of the known biological activity of mast cell-derived mediators, whether they are released as a result of specific IgE/allergen interactions or as the result of nonspecific mechanisms (Kay, 1983). It has been suggested that the events associated with bronchial obstruction may be divided into 3 stages: a rapid spasmogenic phase, a late sustained phase and a subacute/chronic inflammatory phase.

##### 1.4.1 Effect on Bronchial Allergen Challenge

Early studies with beclomethasone dipropionate and sodium cromoglycate (cromolyn sodium) indicated that whereas the latter agent in doses of 20 to 40mg inhibited both the immediate and delayed types of asthmatic reaction, only the late reaction was prevented by beclomethasone dipropionate (Breslin et al., 1973; Pepys et al., 1974). In a more recent study, however, it has been shown that 1 week's pretreatment with beclomethasone dipropionate (400 or 800 µg/day) by pressurised aerosol or dry powder inhalation inhibited the immediate asthmatic reaction induced by appropriate antigen challenge in approximately 50% of asthmatic patients (Burge, 1982).

The effects of budesonide on the 'dual' allergen-induced asthmatic response have been reported in 3 clinical trials (Dahl and Johansson, 1982b,c; Tivenius et al., 1982). In the most comprehensive study (Dahl and Johansson, 1982c), both the immediate and delayed responses to bronchial allergen challenge were evaluated after 12 hours, 1 week and 1 month of pretreatment with inhaled budesonide (fig. 4). The immediate asthmatic reaction (as indicated by percentage fall in peak expiratory flow rate) was increasingly reduced by the longer pe-

riods of budesonide pretreatment, whereas the attenuation of the late allergic reaction was less affected by duration of therapy because of the almost complete blocking of this response during short term treatment.

##### 1.4.2 Effect on Nasal Allergen Challenge

Initial studies with beclomethasone dipropionate 200µg suggested that the immediate reaction to nasal allergen challenge was not inhibited by brief periods (up to 2 days) of intranasal pretreatment (Pelikan and Pelikan-Filipek, 1982). However,




Fig. 4. Comparison of various periods of budesonide pretreatment (□ = 12 hours; ▨ = 1 week; ■ = 1 month) on a control bronchial challenge test (■) in 10 patients known to exhibit a dual bronchial reaction. Pretest peak expiratory flow rates (PEFR) and maximal, immediate, and late responses to allergen challenge were all recorded; \* = significantly different from control values (after Dahl and Johansson, 1982).



study of Pipkorn and effect of budesonide concentrations was measured the number of cells in the concentration in the nasal cell, or a combination of qualitative or quantitative changes in mast cells were present with budesonide in rhinitis patients (Pipkorn). A reduction in the nasal mucosa does not have a mucosal concentration inhibitory effect on the response in asymptomatic allergic rhinitis with budesonide. It is a vasoconstrictor effect on the skin, can account for the intranasal budesonide response to occur in mucosal response placebo in 11 healthy subjects).

**Activity**  
Histamine and slow-reacting substance of anaphylaxis (SRS-A) are the mediators of bronchospasm produced by IgE and/or IgG. Studies with budesonide and beclomethasone dipropionate revealed that budesonide did not protect against anaphylactic shock but both potentiated the response in this test (Forsberg). Furthermore, both drugs reduce histamine release from lung tissue in vitro and on the tissue content of histamine (Forsberg et al., 1982). These results indicate a beneficial effect on the response by inhibiting IgG-mediated release, however, using 2 studies to the formation of response in one model, and

exclusively IgG antibodies in a second model, both budesonide and hydrocortisone reduced *in vivo* anaphylactic bronchoconstriction and *in vitro* histamine release in guinea-pigs sensitised to produce predominantly IgE antibodies (Andersson and Brattsand, 1982). Additionally, *in vitro* studies have shown that pretreatment with intratracheally administered budesonide inhibits IgE-mediated release of mediators participating in both the anaphylactic and inflammatory reactions (leukotrienes  $B_4$  and  $D_4$ , histamine and platelet activating factor) in chopped lungs taken from ovalbumin-sensitised guinea-pigs (Andersson et al., 1984). Finally, it has recently been shown that budesonide and beclomethasone dipropionate are of equal potency in inhibiting IgE-mediated bronchial anaphylaxis in guinea-pigs, but to induce systemic effects a 5- to 10-fold increase in budesonide dosage was required, indicating that it may be the more selective glucocorticoid (Andersson et al., 1983).

#### 1.5 Effect on Bronchial and Nasal Mucosa

Long term application of potent topical corticosteroids to the skin may cause dermal atrophy and the question arises whether similar changes occur in respiratory mucosa following prolonged aerosol or intranasal administration of these agents. Studies with beclomethasone dipropionate have revealed no important changes in bronchial or nasal mucosa following long term administration (Brogden et al., 1984). However, such findings do not necessarily follow for other glucocorticoids and since budesonide has been shown to be more potent than beclomethasone dipropionate when applied topically (see section 1.1), histological assessment of mucosal changes with prolonged use would seem appropriate. In studies in patients with asthma, no evaluations of the effect of inhaled budesonide on bronchial mucosa have been reported. However, histological analysis of nasal mucosal biopsy specimens obtained from patients with rhinitis, treated for up to 1 year with intranasal budesonide, revealed no significant morphological changes in the epithelium such as metaplasia or atrophy compared with pretreatment specimens

(Balle, 1982; Holopainen et al., 1982; Lindqvist et al., 1983; Pipkorn and Berge, 1983).

#### 1.6 Acute Dose-Response Studies

The time course of response to inhaled budesonide has been assessed in double-blind, single-dose, crossover trials in patients with bronchial asthma (Dahl and Johansson, 1982d; Ellul-Micallef and Johansson, 1983a,b; Ellul-Micallef et al., 1980). Each study included 12 patients and the time course of response was evaluated by changes in peak expiratory flow rate (PEFR). When 1000 µg of inhaled budesonide (via a tube spacer) and 40 mg of oral prednisolone were compared with placebo, the peak increase in PEFR was noted 6 to 8 hours after administering budesonide and remained significantly increased for up to 12 hours, whereas for oral prednisolone peak increases were observed between 6 and 10 hours and they remained significantly increased for up to 27 hours (Ellul-Micallef et al., 1980). The increase in PEFR was significantly superior for oral prednisolone from 8 hours onwards.

An acute dose-response study in which 1000 µg of inhaled budesonide, 125 µg of subcutaneously injected terbutaline, a combination of the two, and placebo were all compared, revealed that terbutaline had a peak effect within 1 hour. An increase in PEFR was noted only 4 hours after budesonide but PEFR remained significantly increased throughout the remainder of the 8-hour study (Dahl and Johansson, 1982d). When the 2 drugs were administered simultaneously the bronchodilatory effects appeared additive, with an early increase in PEFR and a more sustained improvement in lung function for the remainder of the trial.

In another study, 3 doses of inhaled budesonide (100, 400 and 1600 µg with a tube spacer) were compared with oral budesonide (1600 µg) and oral prednisolone (40 mg) over a 12-hour period (Ellul-Micallef and Johansson, 1983a) [fig. 5]. All inhaled doses of budesonide produced a significantly greater increase in PEFR than did oral budesonide and when the areas under the PEFR time curves (AUCs) were calculated a dose-response relationship was established. Oral prednisolone was administered 2




Fig. 5. Time course of peak expiratory flow rate (PEFR) response to oral prednisolone ( $\square$ ), oral budesonide 1600 µg ( $\circ$ ) and 3 inhaled doses of budesonide ( $\square$ — $\square$  = 100 µg;  $\Delta$ — $\Delta$  = 400 µg;  $\circ$ — $\circ$  = 100 µg) in 12 patients with bronchial asthma (after Eliul-Micallief and Johansson, 1983a).

days prior to budesonide in a single-blind comparison with placebo, in order to identify corticosteroid responders: the maximum increase in PEFR was significantly greater than that produced by the different inhaled budesonide dosages.

Using a similar protocol in a follow-up study, 2 single doses of budesonide (400 and 1600 µg) were compared with a multiple-dose regimen (4 × 100 µg doses at 2-hour intervals) in patients with bronchial asthma (Ellul-Micallief and Johansson, 1983b). Although the 1600 µg dose resulted in the highest PEFR for the first 7 hours, from the tenth hour onwards the divided regimen was significantly superior. When the change in the AUC of PEFR was compared, there was no significant difference between 1600 µg and 4 × 100 µg and both were a significant improvement over the single 400 µg dose of budesonide. These data highlight the importance of frequency of administration on pulmonary response (see section 3.1.3).

## 2. Pharmacokinetic Studies

There have been only a limited number of trials published in which the pharmacokinetic charac-

teristics of budesonide have been evaluated. In most instances these studies have addressed the problem of explaining the high topical to systemic ratio of activity. However, 2 trials have been reported in which more detailed pharmacokinetic assessments were performed in human volunteers (Ryrfeldt et al., 1982) and in dogs (Ryrfeldt et al., 1979). In addition, a recent investigation studied the individual contribution of the 2 enantiomers of budesonide to the overall pharmacokinetic profile following intravenous administration of  $^3\text{H}$ -budesonide (Ryrfeldt et al., 1984). No pharmacokinetic studies have been reported in patients with asthma or rhinitis.

### 2.1 Absorption

When any drug is given by metered dose inhalation only about 10% of each dose administered enters the lungs, the majority of the remainder being deposited in the mouth and subsequently swallowed (Newman, 1983). Consequently, it is important to establish the oral pharmacokinetic profile of drugs given by aerosol inhalation. In healthy male volunteers 500 µg of  $^3\text{H}$ -budesonide was administered orally, intravenously and by inhalation through a tube spacer (the inhaled dose was corrected for losses in the mouth and in the delivery system, and was calculated to be 260 µg), and the plasma concentrations of total radioactivity and of unchanged drug were measured (Ryrfeldt et al., 1982) (fig. 6). Following inhalation, the highest concentrations of unchanged budesonide were found in the earliest plasma samples (< 1 hour), whereas after oral administration the peak plasma concentrations of unchanged budesonide occurred after 3 hours and those of total radioactivity between 2 and 4 hours. The systemic availability of budesonide was calculated to be 10.7% following oral administration, while 73% of the dose reaching the lung was systemically available, suggesting extensive first-pass metabolism (Ryrfeldt et al., 1982).

Intratracheally instilled  $^3\text{H}$ -budesonide (1 µg/lung) in isolated perfused lungs from guinea-pigs and rats reached equilibrium with the pulmonary




Fig. 6. Plasma concentrations of unchanged drug ( $\circ$ ,  $\square$ ,  $\Delta$ ) for oral, intravenous, and inhalation administration in healthy male volunteers, respectively.

is evaluated. In most studies the problem of the ratio of budesonide to systemic ratio of budesonide has been reported in kinetic assessments in guinea-pigs (Ryrfeldt et al., 1979). In a study of the pharmacokinetic profile following oral administration of  $^3\text{H}$ -budesonide in guinea-pigs, the pharmacokinetic studies with asthma or

by metered dose inhaler dose administered the remainder being subsequently swallowed. In healthy guinea-pigs, the highest budesonide were found in the delivery of the dose (260  $\mu\text{g}$ ), and the radioactivity and of budesonide were found in the highest budesonide were found in the samples (< 1 hour). The peak plasma concentration of budesonide occurred at 10.7% following 10% of the dose reaching the pulmonary (Ryrfeldt et al.,

budesonide (1  $\mu\text{g}$ /g) from guinea-pigs with the pulmonary




Fig. 6. Plasma concentration of total radioactivity (●) and unchanged drug (□) following (a) intravenous, (b) oral and (c) inhalation administration of  $^3\text{H}$ -budesonide 500  $\mu\text{g}$  to 6, 3 and 3 healthy male volunteers, respectively (after Ryrfeldt et al., 1982).

circulation within 5 minutes, illustrating the rapid absorption of budesonide solution through the mucosa and parenchyma of the lung (Brattsand et al., 1982a). When administered intratracheally as micronised particles (< 5  $\mu\text{m}$ ) to guinea-pigs *in vivo*, the major portion of the 100  $\mu\text{g}$  dose ( $\geq 75\%$ ) disappeared from the lungs within the first 20 minutes. Polarisation microscopy indicated that local deposition and dissolution of the micronised particles may be the rate-limiting step in the overall absorption process (Brattsand et al., 1982a). More recently it has been shown that following intratracheal administration of budesonide into guinea-pig lungs *in vitro*, the uptake of budesonide epimer 22R was much greater than that of epimer 22S. Additionally, no metabolites of budesonide were detected in either lung or perfusate samples (unpublished data on file, Astra).

## 2.2 Distribution

Following intravenous administration of  $^3\text{H}$ -budesonide 500  $\mu\text{g}$  to 6 healthy volunteers, the volume of distribution of unchanged drug was calculated to be 301.5L (Ryrfeldt et al., 1982). Recently, using a similar protocol, 500  $\mu\text{g}$  of  $^3\text{H}$ -budesonide was infused intravenously in 6 healthy volunteers and the volumes of distribution of epimer 22R and epimer 22S were found to be 424.9L and 245.1L, respectively (Ryrfeldt et al., 1984). The significantly greater volume of distribution for epimer 22R may be explained by a higher tissue affinity resulting from its more hydrophobic properties.

The plasma protein binding of budesonide *in vitro* was calculated to be 88.3% by equilibrium dialysis and ultracentrifugation, with negligible binding to transcortin (Ryrfeldt et al., 1982).

## 2.3 Elimination

### 2.3.1 Metabolism

Budesonide has been shown to have a high ratio of topical to systemic activity compared with other corticosteroids such as beclomethasone dipropionate, flunisolide, flunisolone acetate and triamcinolone acetonide.

cinolone acetonide (see section 1.1). This difference probably depends on a more rapid rate of biotransformation in the liver (Brattsand et al., 1982b,c,d). At present there are few data currently available concerning the *in vivo* metabolic degradation of budesonide. However, various studies have evaluated the *in vitro* metabolism of budesonide in liver and skin supernatants from several species, including man. Negligible degradation of budesonide, hydrocortisone or triamcinolone acetonide occurred in skin preparations from man, rat or mouse, whereas budesonide was rapidly metabolised in liver preparations from all 3 species (Andersson et al., 1982b) [table I]. Interestingly, budesonide epimer 22R was biotransformed almost twice as quickly as epimer 22S and in a previously reported vasoconstriction assay it was found to be approximately twice as potent (Brattsand et al., 1982c). Similar *in vitro* studies indicate that budesonide is metabolised more rapidly than triamcinolone acetonide and beclomethasone monopropionate (the major step for loss of activity of beclomethasone dipropionate) in human liver preparations (Ryrfeldt et al., 1982). When rat liver preparations were used, budesonide was more rapidly degraded in homogenates from male rats than from female rats and this was reflected in a much reduced systemic potency (as assessed by thymolytic activity) for male rats *in vivo* (Andersson et al., 1982a). These results highlight the greater capacity of the male rat to metabolise drugs generally, probably caused by a higher activity of oxidative enzymes in the liver.

These findings have led a number of workers to conclude that budesonide undergoes extensive first-pass metabolism (Andersson et al., 1982a,b; Brattsand et al., 1982b,c; Ryrfeldt et al., 1979, 1982). Additional indirect evidence for this comes from the finding that the systemic potency of budesonide is increased by liver enzyme inhibition (SKF-525A) and decreased by liver enzyme induction (phenobarbitone) (Brattsand and Källström, 1983).

More recently, an in depth assessment of the metabolic degradation of budesonide was carried out in human liver homogenate *in vitro* (Edsbacker et al., 1983). Two major metabolites identified us-

Table I. Range of *in vitro* metabolic half-lives of various glucocorticoids incubated for 30 minutes in liver supernatants prepared from man, rat and mouse (after Andersson et al., 1982b).

Glucocorticoid	Half-life (minutes)		
	man	rat	mouse
Budesonide	7-23	28-38	17-22
Budesonide epimer 22R	6-16	23-29	7-8
Budesonide epimer 22S	8-38	35-48	26-38
Hydrocortisone	40-67	14-21	82-165
Triamcinolone acetonide	13-68	161-196	21-34

ing this technique were 6 $\beta$ -hydroxybudesonide and 16 $\alpha$ -hydroxyprednisolone. When the 2 epimers of budesonide were incubated separately, no 16 $\alpha$ -hydroxyprednisolone could be detected after incubation of the 22S epimer and this pathway therefore seems to be selective for the 22R epimer. The 2 metabolites identified *in vitro* are present also in human plasma following intravenous administration of budesonide (unpublished data on file, Astra). It has been shown that the 2 metabolites have much less glucocorticoid activity (< 1%) than budesonide (Dahlberg et al., 1984), and the possibility arises that hydroxylation of the 6 $\beta$ -position to form 6 $\beta$ -hydroxybudesonide and loss of the 16 $\alpha$ ,17 $\alpha$ -acetal group to form 16 $\alpha$ -hydroxyprednisolone may be the major metabolic pathways involved in the rapid biotransformation of budesonide into metabolites of low activity.

### 2.3.2 Excretion

In 3 healthy volunteers 45% of the total dose of orally administered <sup>3</sup>H-budesonide 500 $\mu$ g was recovered in the urine and 29.6% in the faeces within the first 96 hours (Ryrfeldt et al., 1982). In the same study, following budesonide 500 $\mu$ g inhalation in 3 volunteers, 31.8% of the dose was recovered in the urine, 15.1% in the faeces, and 41.4% in the mouth or in the exhaled air. In a recent study it was discovered that none or only trace amounts of this total was in the form of unchanged budesonide during the first 24

hours following inhaled budesonide 500 $\mu$ g (Ryrfeldt et al., 1984).

From these studies it is concluded that the half-life of budesonide is about 1 hour (Ryrfeldt et al., 1984). The clearance of budesonide is about 2 L/hour, respectively. These data highlight the high hepatic clearance of budesonide and its high hepatic extraction ratio.

In a study of 10 healthy volunteers it was found that less than 1% of the inhaled budesonide was exhaled air following tidal breathing (Morén and Andersson, 1982).

### 2.3.3 Half-life

The plasma half-life of budesonide is about 1 hour for the 22R epimer and 2 hours for the 22S epimer, respectively. In a study of 10 healthy volunteers (Ryrfeldt et al., 1984) following budesonide 500 $\mu$ g inhalation, the plasma half-life of budesonide was 2.0 hours. This is in agreement with the findings of Ryrfeldt et al. (1982).

## 3. Therapeutic

Inhaled corticosteroids are used in the management of asthma and other respiratory diseases. In the management of asthma, with the exception of beclomethasone dipropionate, the safety of these agents has been evaluated in both short and long-term studies (see Brogden, 1984) and it has become clear that the efficacy of other inhaled corticosteroids is not assessed. Consequently, the proportion of patients using budesonide have increased (usually of open or beclomethasone dipropionate). The following agrees on the

various glu-  
natants pro-  
t al., 1982b)

mouse

17-22

7-8

26-33

82-165

21-34

sonide and  
epimers of  
no 16 $\alpha$ -hy-  
after incu-  
hway there-  
epimer. The  
sent also in  
administra-  
on file. As-  
bolites have  
) than bu-  
ne possibility  
ition to form  
the 16 $\alpha$ ,17 $\alpha$ -  
niscotone may  
olved in the  
ide into me-

e total dose of  
500 $\mu$ g was re-  
: faeces within  
2). In the same  
nhalation in 3  
covered in the  
6 in the mouth  
discovered that  
total was in the  
ing the first 24

hours following intravenous administration of  $^3\text{H}$ -budesonide 500 $\mu$ g to 6 healthy volunteers (Ryrfeldt et al., 1984).

From these studies, plasma clearance of unchanged budesonide was calculated to be 33.7 L/hour (Ryrfeldt et al., 1982) while the plasma clearances of epimers 22R and 22S were 116.8 and 66.7 L/hour, respectively (Ryrfeldt et al., 1984). These data highlight the rapid plasma elimination of budesonide and its 2 epimers and presumably reflect the high hepatic clearance of the compounds.

In a study of 10 healthy volunteers it was found that less than 1% of budesonide was lost in the exhaled air following inhalation, and differences in airflow and tidal volume did not affect this value (Morén and Andersson, 1980).

### 2.3.3 Half-life

The plasma half-lives of unchanged budesonide, epimer 22R and epimer 22S were 2.8, 2.66 and 2.71 hours, respectively, following intravenous administration of  $^3\text{H}$ -budesonide 500 $\mu$ g to 6 healthy volunteers (Ryrfeldt et al., 1982, 1984). Following inhalation, the plasma half-life of unchanged budesonide was 2.0 hours, which is similar to that found after intravenous administration (Ryrfeldt et al., 1982).

## 3. Therapeutic Trials in Asthma

Inhaled corticosteroids are now well established in the management of asthma in steroid-dependent patients, with the great majority of published work and clinical experience being derived from using beclomethasone dipropionate. The efficacy and safety of this agent has been consistently reported in both short and long term trials (for recent reviews see Brogden, 1983a,b,c; Brogden et al., 1984), and it has become the standard against which the efficacy of other inhaled corticosteroids are assessed. Consequently, it is not surprising that a high proportion of published therapeutic trials involving budesonide have been short term comparisons (usually of open crossover design) with beclomethasone dipropionate in patients with asthma of varying degrees of severity (section 3.3). Most of

the remainder of the clinical trials have been short term crossover studies usually evaluating the effects of different doses or different dosing regimens of inhaled budesonide in adult asthmatics. However, some were placebo controlled (Baran, 1984; Henriksen, 1984; Henriksen and Dahl, 1983; Johansson and Dahl, 1984; Rosenhall et al., 1982b), others were only in children with asthma (Baran, 1984; Field et al., 1982; Henriksen, 1984; Henriksen and Dahl, 1983; Kjellman et al., 1982), and a small number were of medium to long term duration (Ådelroth et al., 1984; Laursen et al., 1983; Rosenhall et al., 1982a). Some of the trials have been presented as short reports or in letter form, which has complicated their evaluation because of the lack of essential information concerning patients, trial design, methods, and so forth (Dahl and Johansson, 1982a; Kjellman et al., 1982; Laursen et al., 1983; Sliksa et al., 1982; Toogood, 1983).

Considering that inhaled corticosteroids are intended for the longer term prophylaxis of asthma rather than the treatment of acute exacerbations, there seems to be an undue preponderance of studies of between 2 and 4 weeks duration (2 weeks being by far the most frequent duration of assessment for each active regimen or any given particular dose). Only a limited number of trials have been reported in which budesonide was administered for prolonged periods (section 3.2). While these studies showed a convincing steroid-sparing effect in patients with severe asthma, the relative efficacy of budesonide compared with other inhaled corticosteroids has not been assessed in long term studies.

### 3.1 Short Term Studies in Asthma

Even after single doses, inhaled budesonide produces a rapid improvement in pulmonary function characterised by a dose-response increase in peak expiratory flow rate (section 1.6). Following multiple doses (25, 100 or 400 $\mu$ g 4 times a day) in an appropriately designed 2-week crossover study in 18 patients with moderately severe asthma, dose-dependent increases in morning and evening peak

expiratory flow rates were also recorded (Johansson and Dahl, 1984) [fig. 7].

In this study there was a high drop-out rate during the placebo period which suggests that all 3 doses of budesonide were more effective than placebo, although 2 patients also withdrew while receiving the lowest dose of budesonide. Assessment of subjective scores for asthma severity revealed that budesonide 400 and 1600  $\mu\text{g/day}$  was superior to 100  $\mu\text{g/day}$ , but only a daily dose of 400  $\mu\text{g}$  was statistically different from placebo.

### 3.1.1 Inhaled Budesonide Compared with Oral Steroids

In severe steroid-dependent asthmatics, long term therapy with high dose oral steroids produces an increased incidence of side effects (Cochrane, 1983). Because of this, any oral steroid-sparing manoeuvre should be considered if disease stability can be maintained: a number of studies have attempted to compare the antiasthmatic efficacy of inhaled budesonide with that of oral prednisone.

In an open randomised 2-week crossover study in 16 patients with steroid-dependent severe asthma, daily doses of 400 and 800  $\mu\text{g}$  of inhaled

budesonide appeared to be of equivalent potency as 10 and 20mg of oral prednisolone, as assessed by changes in peak expiratory flow rate and severity of asthmatic symptoms (Rosenhall et al., 1982b). In a double-blind crossover study, 14 prednisone-dependent patients and 17 patients not requiring oral steroid received 3 dosages of inhaled budesonide (400 to 3200  $\mu\text{g/day}$ ) and 3 dosages of alternate-day oral prednisone (7.5 to 60mg) for 2 weeks each (unpublished data on file, Astra; Toogood et al., 1983). After a stable baseline period (maintained with inhaled beclomethasone dipropionate with or without alternate-day oral steroid), it was impossible to adequately control asthmatic symptoms with alternate-day oral prednisone alone in prednisone-dependent patients. In contrast, budesonide alone, inhaled with the aid of a spacer, significantly improved asthma control, the best response being obtained with 800 to 1600  $\mu\text{g/day}$ . In both prednisone-dependent patients and those not dependent upon oral prednisone, inhaled budesonide was superior to alternate-day oral prednisone in controlling asthma, as assessed by forced expiratory volume, severity of symptoms and attack frequency.

Comparable findings have been reported in 34 patients with severe unstable asthma requiring high doses of oral prednisone on alternate days (Toogood et al., 1984d). Patients received both inhaled budesonide (400 to 3200  $\mu\text{g/day}$  in 4 divided doses) and oral prednisone (7.5 to 40mg once daily) for 6 weeks each, the actual dose being dependent upon the prior severity of the underlying disease. In a double-blind crossover trial. Relapses of asthma were linearly related to the log dose of both drugs but the number of exacerbations requiring extra oral steroid occurred twice as often with oral prednisone ( $p < 0.05$ ) and the relative potency for preventing severe relapses was 25:1 in favour of inhaled budesonide. The results of this study indicate that both inhaled budesonide and oral prednisone can effectively control unstable asthma providing that sufficiently large doses are used. However, at doses producing equivalent control of the asthmatic condition, inhaled budesonide had significantly less systemic activity, as measured by morn-

ing serum corticosteroid levels. It is not to say that even low doses of inhaled budesonide produce significant adrenal suppression: investigators have produced a cortisol concentration of 1.31.

Similarly, in inhaled budesonide compared with inhaled beclomethasone, budesonide produced greater rates than 20% in severely asthmatic patients. In a study of doses of oral prednisone (1982b). However, it is difficult due to the long half-life of prednisone to achieve a steady state for prednisone inhaled dosage.

### 3.1.2 Budesonide

Several short-term studies have assessed the clinical efficacy of inhaled budesonide in children with asthma. In comparisons with oral prednisone (see section 3.2), budesonide was of approximately equivalent efficacy (1982). Kjellman's double-blind crossover study of budesonide spacer was found to produce improvements in peak expiratory flow rate and asthma severity comparable to oral prednisone. Another double-blind crossover study investigated the effect of budesonide (32.5  $\mu\text{g}$ ) with exercise-induced asthma over a 7-week treatment period. In a study by Dahl (1983). The results suggest that budesonide is less effective than oral prednisone in controlling asthma, but less effective in controlling asthma symptoms.




Fig. 7. Mean evening peak expiratory flow rates after  $\geq 1$  week run-in period (on inhaled beclomethasone dipropionate 400  $\mu\text{g/day}$ ), three 2-week treatment periods with different doses of inhaled budesonide (100, 400, and 1600  $\mu\text{g/day}$  in 4 divided doses) and a 2-week placebo-controlled washout period in 18 patients with moderately severe asthma: \*  $p < 0.05$ , \*\*  $p < 0.01$  compared with placebo (after Johansson and Dahl, 1984).



valent potency  
ne, as assessed  
rate and sever-  
ill et al., 1982b).

14 prednisone-  
is not requiring  
f inhaled bude-  
3 dosages of al-  
to 60mg) for 2  
file, Astra; Too-  
baseline period  
methasone dipro-  
-day oral steroid),  
control asthmatic  
1 prednisone alone  
s. In contrast, bu-  
ic aid of a spacer,  
ontrol, the best re-  
to 1600 µg/day. In  
ients and those not  
e, inhaled budeson-  
lay oral prednisone  
sed by forced expi-  
mptoms and attack

been reported in 34  
asthma requiring high  
alternate days (Too-  
received both inhaled  
lay in 4 divided doses)  
10mg once daily) for 6  
being dependent upon  
underlying disease, in a  
1. Relapses of asthma  
log dose of both drugs  
ions requiring extra oral  
often with oral predni-  
clative potency for pre-  
is 25:1 in favour of in-  
ults of this study indicate  
side and oral prednisone  
stable asthma providing  
es are used. However, at  
ent control of the asth-  
1 budesonide had signifi-  
ity, as measured by morn-

ing serum cortisol concentrations and blood  
eosinophil and neutrophil counts. However, this is  
not to say that continuous regular use of such doses  
of inhaled budesonide would not cause some adre-  
nal suppression; indeed, data from the same in-  
vestigators have already shown that budesonide  
produces a dose-dependent decrease in serum cor-  
tisol concentrations (Toogood et al., 1982b) [sec-  
tion 1.3].

Similarly, in a placebo-controlled study, both  
inhaled budesonide 200 and 800 µg/day and in-  
haled beclomethasone dipropionate 400 µg/day  
produced greater increases in peak expiratory flow  
rates than 30 mg/day of oral prednisolone in 23  
severely asthmatic patients maintained on a mix-  
ture of drugs, including minimum maintenance  
doses of oral corticosteroids (Rosenhall et al.,  
1982b). However, interpretation of these data is  
difficult due to a number of faults in the trial de-  
sign and the difference in treatment duration - 1  
week for prednisolone and 2 weeks for each in-  
haled dosage.

### 3.1.2 Budesonide in Asthmatic Children

Several short term therapeutic trials have ev-  
aluated the clinical efficacy of inhaled budesonide  
in children with asthma. Some of these were direct  
comparisons with beclomethasone dipropionate  
(see section 3.3), which indicated that the 2 drugs  
were of approximately equal potency (Field et al.,  
1982; Kjellman et al., 1982). However, in a recent  
double-blind crossover trial in 21 asthmatic child-  
ren, budesonide 100µg twice daily inhaled with a  
spacer was found to produce significantly greater  
improvements in morning and evening peak ex-  
piratory flow rates and in forced expiratory volume  
than equal doses of beclomethasone dipropionate  
inhaled with a standard actuator (Baran, 1984).  
Another double-blind placebo-controlled study in-  
vestigated the effect of single doses of inhaled ter-  
butaline (32.5µg) on lung function in 14 children  
with exercise-induced asthma before and during 4  
weeks' treatment with inhaled budesonide (400 µg/  
day through a 750ml cone spacer) (Henriksen and  
Dahl, 1983). The main aim of the trial was to as-  
sess whether sustained therapy with budesonide

could possibly potentiate the effects of terbutaline;  
the results support the view that the interaction be-  
tween the 2 drugs was probably additive. At rest,  
1 week's treatment with budesonide produced a  
significant improvement in lung function, as as-  
sessed by changes in peak expiratory flow rate,  
forced expiratory volume in one second and forced  
expiratory flow in the middle half of forced vital  
capacity, and there was a further small improve-  
ment by week 4. The bronchoconstrictor response  
to exercise was reduced following 4 weeks' treat-  
ment with budesonide and this mirrors the find-  
ings obtained with other inhaled corticosteroids -  
single doses of which did not inhibit exercise-in-  
duced asthma but therapy for 2 to 4 weeks did af-  
ford some protection (Hartley et al., 1977; Hodg-  
son et al., 1974). As a follow-up to this trial the  
effectiveness of inhaled budesonide (400 µg/day  
with a spacer) in preventing exercise-induced  
asthma was evaluated in a 3-week double-blind  
placebo-controlled crossover study in 16 asthmatic  
children (Henriksen, 1984). Of 14 children who  
completed the trial, 12 gained significant protec-  
tion from exercise-induced asthma while receiving  
budesonide and the mean fall in forced expiratory  
volume after exercise was reduced by 63%.

### 3.1.3 Twice Daily vs Four Times Daily Administration

Experience with beclomethasone dipropionate  
indicates that moderate asthma can be well con-  
trolled with a twice or 4 times daily dosing sched-  
ule when the asthma is stable (Bjergaard et al., 1980).  
Since poor compliance has been implicated as a  
possible factor in reducing the efficacy of inhaled  
corticosteroids, any reduction from the conven-  
tional 4-times-a-day regimen may help improve  
compliance and consequently the efficacy of in-  
haled steroids.

In a number of studies, budesonide inhaled twice  
daily has proved to be as effective as beclometha-  
sone dipropionate inhaled 4 times a day in patients  
with chronic asthma (Willey et al., 1982), steroid-  
dependent severe asthma (Sticks et al., 1982), and  
in children with severe asthma (Field et al., 1982).  
When budesonide (800 µg/day) was administered

both twice and 4 times daily, no reduction in therapeutic efficacy was observed as a result of reducing the dose frequency (Stiksa et al., 1982). These findings were supported by the results of a recent study in which twice and 4 times daily administration of budesonide (400 µg/day with a spacer) were compared in a double-blind 4-week crossover trial in 19 patients with stable asthma not requiring oral steroids (Nyholm et al., 1984). Assessment of pulmonary function (peak expiratory flow rate, forced expiratory volume and forced vital capacity) and asthma symptoms indicated that twice daily treatment with budesonide was at least as effective as a 4 times daily regimen. However, in a comprehensive study specifically designed to evaluate the influence of various dosing regimens on the response of 34 severely asthmatic patients to aerosol budesonide, daily doses of 400, 800 and 1600 µg were administered 2 or 4 times a day for 2 weeks each in a crossover trial (Toogood et al., 1982a,b). At every dose level of budesonide the best results (regardless of index measured) were consistently observed with the 4 times daily dose regimen. In agreement with these results are the findings of Dahl and Johansson (1982a) who showed that a reduction in dose frequency from 4 times daily to twice daily in 16 patients with moderately severe asthma produced a significant decrease in evening peak expiratory flow rate, although the morning rate was unchanged. The apparently contradictory conclusions drawn from these trials may reflect differences in the activity of the asthmatic state of the patients studied. Whether the small (but statistically significant) improvements in lung function in favour of the more frequent dosing regimens found in some short term studies do indeed afford greater antiasthmatic protection against periods of acute exacerbation remains uncertain. However, until this matter is clarified it may be clinically prudent, especially for patients in relapse where a more frequent budesonide regimen has been shown to be significantly superior, to employ a 4-times-a-day dosing schedule.

### 3.1.4 Effect of Spacer Devices

In a number of trials budesonide has been ad-

ministered with an extension or spacing (spacer) device (for examples see table II). This could be an important consideration when evaluating such studies since it has been shown that these devices can increase drug deposition in the lung and decrease unwanted deposition in the oropharynx (Newman et al., 1981). In the study of Björkander et al. (1982) it was shown that budesonide 50 µg 4 times daily inhaled through a spacer was slightly more efficacious, with respect to reducing the need for supplemental  $\beta_2$ -agonists and in relieving symptoms, than an equivalent dose of budesonide or beclomethasone 100 µg 4 times daily, both administered with a standard actuator. However, each treatment period was only 2 weeks in duration and changes in peak expiratory flow were not significantly different.

In studies designed to specifically evaluate the influence of an 80 ml tube spacer, a 750 ml cone spacer, and a conventional actuator for administering low (400 µg/day) and high (1600 µg/day) doses of budesonide to 35 asthmatics it was found that both spacers may be clinically useful in that they augment the airway response to budesonide and reduce the level of oropharyngeal candidiasis (section 6.1.1) (Toogood et al., 1982b,c). The 2 spacers doubled the antiasthmatic potency of inhaled budesonide as assessed by the change in forced expiratory volume in 1 second from baseline ( $p < 0.05$ ), and this occurred despite preselecting and pretraining this group of patients to achieve maximum efficiency using a standard actuator. The results from this study indicate that all asthmatic patients receiving budesonide deserve a trial with a spacer, since approximately 90% of them may be expected to show an improvement in asthma control and/or reduced oropharyngeal complications, and at present there is no accurate method of predicting those likely to respond (Toogood et al., 1982c).

### 3.2 Long Term Studies in Asthma

Long term trials with inhaled budesonide have all been of open design in patients with severe asthma; assessments were made to evaluate changes

in lung function for oral steroid tapering (asthmatic patients entered an 8-week safety and efficacy trial of daily inhaled budesonide 134 patients and of the 33 adverse effects: (such as decreased underlying reasons. Due requiring sup though controlled since patients require, as assessed significantly in ment period, vital capacity increases in capacity were compared increases at ment in the symptom ness of the nificantly r respiratory patients participated any new eff year, although tistical and

All other dependent ly assessed ment for e inhaled b dependent as were treat 1000 µg/d sumption 2.5 mg (B mean per

ing (spacer) could be an evaluating such these devices lung and de-oropharynx of Björkander sonide 50µg 4 r was slightly izing the need in relieving of budesonide ily, both ad-However, each 1 duration and re not signifi-

ly evaluate the a 750ml cone or for admini-(1600 µg/day) es it was found y useful in that to budesonide geal candidiasis 984b,c). The 2 : potency of in-the change in cond from base-d despite prese-p of patients to g a standard ac-indicate that all sonide deserve a tely 90% of them improvement in d oropharyngeal re is no accurate to respond (Too-

thma

i budesonide have ents with severe o evaluate changes

in lung function and symptomatology, and the need for oral steroids and hospitalisation (for acute exacerbations). In the largest study to date, 166 adult asthmatics dependent upon inhaled steroids entered an 8-centre trial designed to investigate the safety and efficacy of budesonide 100µg 4 times daily inhaled via a spacer (unpublished trial, Astra). 134 patients completed 1 year of treatment and of the 32 withdrawals only 10 were due to adverse effects: 14 were due to other medical reasons (such as deterioration or improvement of the underlying disease) and 8 were for non-medical reasons. During the trial the number of patients requiring supplemental oral steroids decreased, although conclusions with respect to this should be guarded since only a small percentage (18.7%) of patients required oral steroids at entry. Lung function, as assessed by forced expiratory volume, significantly improved during the 12-month treatment period, but there was no change in forced vital capacity. In addition, bronchodilator-induced increases in forced expiratory volume and vital capacity were significantly reduced during follow-up, compared with the bronchodilator-induced increases at baseline. In parallel with the improvement in lung function, daytime and night-time symptom scores for wheeze, breathlessness, tightness of the chest, cough and sputum were all significantly reduced throughout follow-up, and the respiratory rate was also significantly decreased. 77 patients continued for a second year (only 4 centres participated) and the results did not appear to show any new effects or changes compared with the first year, although firm conclusions await separate statistical analysis for this subgroup.

All other long term trials have been in patients dependent upon oral prednisone and have primarily assessed the possibility of reducing the requirement for oral steroid during high dose therapy with inhaled budesonide. Thus, in 31 prednisolone-dependent asthmatics (mean duration 12.3 years) who were treated with inhaled budesonide (mean dose 1060 µg/day) for 12 months, the mean daily consumption of oral steroid was reduced from 9 to 2.5mg (Rosenhall et al., 1982a). During the trial, mean peak expiratory flow rate increased from 250

to 320 L/min in the morning and from 320 to 260 L/min in the evening, with those patients who had the highest prednisolone intake at the start of the study gaining the most benefit. Additionally, there was a marked reduction in the number of exacerbations of asthma per month and a gradual increase in plasma cortisol concentrations (see section 1.3). As a continuation of this trial, 38 patients with chronic asthma requiring continuous oral corticosteroids (87% required 5 to 15mg of prednisolone each day and the remainder were on alternate-day therapy) were followed for 2 years, and during this period budesonide (inhaled via a tube spacer) was carefully substituted for the oral ster-




Fig. 2. Summary of patients' requirement for oral steroid (compared with baseline) after 2 years' therapy with high dose inhaled budesonide (200 to 1500 µg/day) in an open study of 38 patients with steroid-dependent severe asthma (after Ågerholm et al., 1984).

oid (Ådelroth et al., 1984). At the end of 2 years the majority of patients were able to stop the use of, or greatly reduce ( $\geq 50\%$ ) the need for, oral prednisolone (fig. 8). Comparing the second year of the trial with the year preceding it, hospital ad-




Fig. 9. Mean values of peak expiratory flow rate (PEFR) and supplemental  $\beta_2$ -agonist usage during 14-day assessment periods, before (□) and during high dose prednisone treatment (▨) and after 6 months' therapy with budesonide 1600  $\mu$ g/day (▨) in a 6-month prospective study in 49 patients with severe asthma: \*  $p < 0.05$ ; \*\*  $p < 0.001$  compared with corresponding values before treatment (after Laursen et al., 1983).

missions and the number of days of treatment caused by acute attacks of severe asthma were reduced by 73% and 76%, respectively. During the study, half the reduction of oral steroid was achieved in the first 3 months and was almost completed within 6 months. At the same time, morning and evening peak expiratory flow rates considerably increased and total symptom scores reduced by approximately 33%.

Findings of a similar nature were observed in a prospective 6-month controlled trial in 49 steroid-dependent (prednisone 10 to 40mg daily) severe asthmatics whose mean disease duration was 18 years (Laursen et al., 1983). Before initiating therapy with aerosol budesonide 800 $\mu$ g twice daily with a spacer, each patient underwent 7 days' treatment with prednisone 40mg to establish near maximal bronchodilation. By the end of the study oral prednisone intake was reduced from 13.9 to 6.0 mg/day and lung function, as assessed by peak expiratory flow rate, was greatly improved (20% in the morning and 10% in the evening); there was also a concomitant significant reduction in the requirement for supplemental  $\beta_2$ -agonist inhalations (fig. 9).

The lack of placebo controls in all of these trials might have masked any tendency for spontaneous improvement in asthmatic status that can occasionally occur, but this seems unlikely considering the severity of the underlying disease. The striking improvements observed are encouraging but further long term studies are needed to clearly establish the place of inhaled budesonide in the treatment of asthma compared with other available inhaled corticosteroids.

### 3.3 Budesonide Compared with Other Inhaled Corticosteroids

Beclomethasone dipropionate is the most widely studied inhaled steroid available for the treatment of asthma, and it is the standard by which newer inhaled steroids are compared. It is therefore not surprising that all the comparative studies involving budesonide have been with beclomethasone dipropionate (table II). In design, a small number of

Table II. Summary of design and results of short term therapeutic trials comparing aerosol budesonide (BUD) and beclomethasone dipropionate (BDP) in the treatment of asthma

Reference	No. of patients*	Diagnosis	Study design	Duration of therapy <sup>b</sup> (weeks)	Daily dosage (mg/day)		Assessment criteria	Overall results
					BUD	BDP		

of treatment asthma were reliably. During the steroid was almost the same time, expiratory flow rates and symptom scores

observed in a study in 49 steroid-dependent (daily) severe asthmatic patients. Initiating therapy with a low daily dose of budesonide (200 µg) near maximal oral prednisolone (9 to 6.0 mg/day) by peak expiratory flow rate (20% in the study) here was also in the required inhalations

of these trials. Spontaneous remission can occur, considering the striking improvement but further establishing in the treatment available

After Inhaled

most widely used in the treatment of asthma, which newer therapies have not yet involved. Budesonide di-

Table II. Summary of design and results of short term therapeutic trials comparing aerosol budesonide (BUD) and beclomethasone dipropionate (BDP) in the treatment of asthma

Reference	No. of patients <sup>a</sup>	Diagnosis	Study design	Duration of therapy <sup>b</sup> (weeks)	Daily dosing (frequency)		Assessment criteria	Overall results <sup>c</sup>
					BUD	BDP		
Baran (1984)	21	Children with chronic asthma	r, db, co, pc	3	200 µg (bid) <sup>d</sup>	200 µg (bid)	PEF, FEV <sub>1</sub> , VC, and diary cards	BUD > BDP
Bjorkander et al. (1982)	12	sd, stable, moderate asthma	r, co, pc	2	400 µg (qid)	400 µg (qid)	PEF, FEV <sub>1</sub> , VC and diary cards	BUD = BDP
Bjorkander et al. (1982)	23	sd, stable, moderate asthma	r, co, pc	2	200 µg (qid) <sup>d</sup>	400 µg (qid)	PEF, FEV <sub>1</sub> , VC and diary cards	BUD = BDP
Field et al. (1982)	27	Children with severe asthma	r, db, co	4	400 µg (bid) <sup>d</sup>	400 µg (qid)	PEF, FEV <sub>1</sub> , VC and diary cards	BUD > BDP
Kjellman et al. (1982)	18	Children with severe, sd asthma	r, open, co	3	full dose (bid) <sup>d</sup> half dose (bid) <sup>e</sup>	full dose (bid) full dose (bid)	PEF and symptom scores	BUD = BDP BUD = BDP
Rosenhall et al. (1982b)	23	sd, severe asthma	r, open, co	2	200 µg (qid) 800 µg (qid)	400 µg (qid)	PEF, FEV <sub>1</sub> , VC and diary cards	BUD = BDP
Saksela et al. (1982)	27	sd, severe asthma	r, open, co	2	800 µg (qid) 800 µg (bid)	800 µg (qid)	PEF and diary cards	BUD = BDP BUD = BDP
Wiley et al. (1982)	30	nsd, chronic asthma	r, db, co	4	400 µg (tid) <sup>d</sup>	400 µg (qid)	PEF, FEV <sub>1</sub> , VC and diary cards	BUD = BDP

a Number of patients who completed the trial.

b Duration of treatment with each active regimen.

c BUD = BDP signifies that the 2 drugs produce equivalent changes; BUD > BDP indicates a trend in favour of budesonide; BUD < BDP indicates that beclomethasone dipropionate was significantly better than budesonide.

d Administered with and without a spacer.

e Administered with a spacer.

Abbreviations: db = double-blind; co = cross-over; r = randomised; pc = placebo-controlled; sd = steroid-dependent; nsd = non-steroid-dependent; bid = twice daily; qid = 4 times daily; PEF = peak expiratory flow rate; FEV<sub>1</sub> = forced expiratory volume in one second; VC = vital capacity.

the trials were double-blind (Baran, 1984; Field et al., 1982; Willey et al., 1982); the remainder were non-blind - all were randomised crossover comparisons in patients with asthma of reasonably well-defined severity. The duration of treatment was short term (between 2 and 4 weeks) in every study and, since there is a strong carryover of antiasthmatic effects with inhaled corticosteroids, it would seem unlikely that trials of such short duration could detect small therapeutic differences in 2 drugs of similar activity.

Drug-induced changes in asthmatic status were assessed by peak expiratory flow rate and symptom scores in every study, and also by changes in forced expiratory volume in one second and vital capacity in most other trials (see table II). The majority of studies show that with short term use inhaled budesonide and inhaled beclomethasone dipropionate are of approximately equal efficacy in children with asthma (Field et al., 1982; Kjellman et al., 1982), in steroid-dependent asthmatics (Björkander et al., 1982; Rosenhall et al., 1982b; Stiksa et al., 1982) and in patients not dependent upon oral prednisolone (Willey et al., 1982). The only trial to find any significant differences between these 2 inhaled corticosteroids was the study of Baran (1984): budesonide administered with a spacer to asthmatic children was significantly superior to beclomethasone dipropionate (see section 3.1.2). However, the different methods of administering the 2 drugs makes it difficult to interpret the findings in terms dose equivalency. The relative efficacy of budesonide and beclomethasone dipropionate following long term administration has not been reported.

#### 4. Therapeutic Trials in Rhinitis

The therapeutic efficacy of intranasal budesonide has been evaluated in patients with seasonal allergic, perennial allergic and perennial non-allergic (vasomotor) rhinitis in open, single-blind and double-blind trials. In the majority of studies comparisons were made with placebo although there have also been a number of comparisons with other active treatments. These include single-blind com-

parisons with beclomethasone dipropionate (Pipkorn, 1983b; Pipkorn and Runderantz, 1982; Samuelsson, 1983), a single-blind comparison with flunisolide (Pipkorn and Geterud, 1984), a single- and a double-blind comparison with sodium cromoglycate (unpublished trial on file, Astra) and a double-blind comparison with the antihistamine dexchlorpheniramine (Munch et al., 1983).

Since there is no proven and reliable technique for measuring the severity of symptoms associated with rhinitis, subjective assessment of changes in disease status, as recorded on patient symptom diary cards, has been the most extensively used method. Recently, rhinomanometry has been used to determine nasal airway resistance in patients with non-allergic perennial rhinitis (Malin et al., 1981) and in children with perennial allergic rhinitis associated with bronchial asthma (Wenzel et al., 1983), although in the former study the results did not correspond with nasal symptom scores or nasal secretion following methacholine challenge.

##### 4.1 Comparisons with Placebo in Seasonal Allergic Rhinitis

Due to the seasonal nature of the disease and because spontaneous variation in atmospheric allergen levels occur, it is desirable that therapeutic trials in patients with seasonal allergic rhinitis should be placebo-controlled. It is also essential that pollen counts are recorded to indicate the severity of exposure. Several short term placebo-controlled double-blind comparisons in parallel groups of patients have been reported with budesonide (Cameron et al., 1984; Norman et al., 1984; Pipkorn et al., 1980; Steensen and Lindqvist, 1981; Warland et al., 1981) (table III). Most of these trials were performed in Scandinavia (Denmark, Norway and Sweden) although one was carried out in a general practice setting in England (Cameron et al., 1984) and one was carried out in the United States (Norman et al., 1984).

The results from these trials have shown intranasal budesonide 400 µg/day to be significantly more effective than placebo in relieving nasal symptoms (blockage, discharge and sneezing) and

Table III. Summary of comparisons with placebo in patients with seasonal allergic rhinitis

Reference
Cameron et al. (1984)
Norman et al. (1984)
Pipkorn et al. (1980)
Steensen and Lindqvist (1981)
Warland et al. (1981)
Wenzel et al. (1983)
Malin et al. (1981)
Helebrand et al. (1983)
Malin et al. (1981)
Wenzel et al. (1983)
a. Number of patients
b. EUD > P > B
c. Children > P > B
d. Patients > P > B
e. Patients > P > B
f. Patients > P > B
Abbreviations:

in reducing tablets. In the study of Wenzel (1983) the effect of budesonide was verified in a double-blind trial whether the effect was verified in the study of the effect on the receiving intr

opionate (Pip-  
ntz, 1982; Sa-  
nparison with  
994), a single-  
with sodium  
ile, Astra) and  
antihistamine  
1983).

ible technique  
ms associated  
of changes in  
ent symptom  
ensively used  
has been used  
patients with  
a et al., 1981)  
gic rhinitis as-  
Wenzel et al.,  
the results did  
scores or nasal  
allenge.

#### Seasonal

e disease and  
mospheric al-  
at therapeutic  
lergic rhinitis  
essential mat-  
e the severity  
do-controlled  
el groups of  
a budesonide  
IL, 1984; Pip-  
idqvist, 1981;  
of these trials  
nmark, Nor-  
carried out in  
(Cameron et  
a the United

shown intra-  
significantly  
lieving nasal  
sneezing) and

Table III. Summary of the design and results of studies comparing budesonide (BUD) administered twice daily with placebo (P) in patients with seasonal or perennial rhinitis

Reference	No. of patients <sup>a</sup>	Study design	Daily dosage (µg)	Duration of therapy (weeks)	Results <sup>b</sup>			
					nasal symptom score	eye symptom score	supplementary antiallergy drugs	nasal airway resistance
<i>Seasonal rhinitis</i>								
Cameron et al. (1984)	60	db, pg	400	4	BUD > P	BUD < P	BUD > P	
Norman et al. (1984)	50	db, pg	400	4	BUD > P			
Pepkorn et al. (1980)	36	db, pg	400	3	BUD > P		BUD > P	
Steensen and Lindqvist (1981)	30	db, pg	200 400	2	BUD > P	BUD = P	BUD > P	
Warland et al. (1981)	29	db, pg	400	3	BUD > P		BUD > P	
<i>Perennial rhinitis</i>								
Balla et al. (1980) <sup>c</sup>	26	db, co	200 400	2	BUD > P			
Henniksen and Wenzel (1983) <sup>d</sup>	35	db, pg	400	4	BUD > P			
Holopainen et al. (1982) <sup>e</sup>	19	db, pg	400	16	BUD > P			
Malm et al. (1981) <sup>f</sup>	22	db, co	50, 200 and 800	2	BUD > P			BUD = P
Wenzel et al. (1983) <sup>g</sup>	37	db, pg	400	4				BUD > P

<sup>a</sup> Number of patients who completed the trial.

<sup>b</sup> BUD > P signifies that budesonide produced a significantly more favourable response than placebo; BUD = P indicates that budesonide and placebo produced equivalent changes; BUD < P signifies that placebo produced a significantly better response.

<sup>c</sup> Children with bronchial asthma and perennial allergic rhinitis.

<sup>d</sup> Patients with perennial non-allergic rhinitis.

<sup>e</sup> Patients with allergic or non-allergic rhinitis.

<sup>f</sup> Patients with nasal polyps.

Abbreviations: db = double-blind; co = crossover; pg = parallel groups of patients used.

in reducing the need for supplemental antiallergy tablets. In one of these trials (Steensen and Lindqvist, 1981) budesonide 200 µg/day was effective in alleviating nasal symptoms, but this study was performed in a season when pollen counts were low; whether this dosage regimen would be equally effective during periods of high exposure remains to be verified. Budesonide was found to have no effect on the severity of eye symptoms. Indeed, in the study of Cameron et al. (1984), patients receiving intranasal budesonide 400 µg/day had sig-

nificantly more severe eye symptoms than did a placebo group, although they did not resort to using more eye drops to relieve these symptoms. In contrast, in the trial of Steensen and Lindqvist (1981) patients in the budesonide group did use more eye drops to alleviate eye symptoms than did a placebo group, and consequently no significant change in total eye symptoms could be demonstrated between the groups. A similar lack of effect on eye symptoms has been observed when using intranasal beclomethasone dipropionate in patients

with seasonal allergic rhinitis (Brogden et al., 1984).

In a study of 50 grass-allergic patients characterised by spring hayfever, symptom scores were significantly reduced ( $p = 0.001$ ) by intranasal budesonide compared with placebo (Norman et al., 1984). Mediator analysis from nasal washes revealed that histamine content was not significantly altered by treatment, whereas the concentration of another allergic mediator [tosyl-arginine methyl ester (TAME)-esterase] was significantly lowered by budesonide (3594 to 1759 counts/min) but not by placebo (3019 to 3385 counts/min).

#### 4.2 Trials in Perennial Rhinitis

Perennial vasomotor rhinitis is a common and frequently very uncomfortable condition that is characterised by non-seasonal sneezing, nasal discharge, and nasal congestion. It is normally termed 'allergic' when a specific allergen is considered responsible and 'vasomotor' when no such allergic component can be identified (Balle et al., 1980). Intranasal budesonide has been used in the treatment of allergic and non-allergic perennial rhinitis. Both double-blind comparisons with placebo (table III) and long term open trials have been published (Balle, 1982; Lindqvist et al., 1982, 1983; Pipkorn and Berge, 1983), but the failure in some of these studies to clearly distinguish between allergic and non-allergic patients makes interpretation of the results difficult in such cases.

##### 4.2.1 Placebo-Controlled Studies

Placebo-controlled double-blind comparisons have shown intranasal budesonide to be superior to placebo in patients with perennial non-allergic rhinitis (Malm et al., 1981), perennial allergic or non-allergic rhinitis (Balle et al., 1980), perennial non-allergic rhinitis with small nasal polyps (Holopainen et al., 1982), and in children with perennial allergic rhinitis associated with bronchial asthma (Henriksen and Wenzel, 1983; Wenzel et al., 1983). Generally, daily doses of 200 or 400 µg have proved effective although a dose of 50 µg/day was also found to significantly relieve nasal symptoms (without significantly reducing methacholine-in-

duced secretions) in patients with non-allergic rhinitis (Malm et al., 1981). In this study budesonide was administered intranasally at 3 dosages – 50, 200 and 800 µg/day – but no clear dose-response relationship was observed and there was no statistically significant difference between any of the 3 dosages and placebo, with respect to changes in nasal airway resistance measured rhinomanometrically. In contrast, approximately half the patients had nasal eosinophilia before treatment and this was significantly reduced by budesonide so that after the last treatment period only 2 patients had nasal eosinophilia. A similar finding was observed in patients with perennial rhinitis with associated nasal polyposis, in whom intranasal budesonide caused a pronounced reduction in tissue eosinophilia (Holopainen et al., 1982). A previous placebo-controlled double-blind trial noted budesonide was effective in patients with vasomotor and allergic rhinitis, but when they were subdivided regarding nasal eosinophilia, budesonide was only effective in those with eosinophilia (Balle et al., 1980).

##### 4.2.2 Open Studies

Budesonide has been used in several long term open trials in patients with perennial rhinitis, but in one of these (Balle, 1982) only adverse reactions to treatment were reported in 15 patients treated for up to 30 months (see section 6.2). In a recently reported study (Pipkorn and Berge, 1983), 12 patients with vasomotor rhinitis received intranasal budesonide for 1 year. Initial dosage was 400 µg/day and symptoms were consistently relieved throughout the study period and no symptom relapse was observed; at the end of the trial 3 patients had reduced their daily dosage to 200 µg and no dosage increases were required. A 6-month open study in 86 patients with perennial rhinitis (in 38 it was classified as allergic) showed that intranasal budesonide 200 to 400 µg/day significantly reduced severity of all nasal symptoms after 2 and 6 months of therapy (Lindqvist et al., 1982). Similarly, in a 12-month open study in 106 adults with perennial rhinitis, intranasal budesonide (200 to 400 µg/day) produced a significant decrease in all nasal symptoms (Lindqvist et al., 1983).

The conclusions have been that budesonide is effective in perennial rhinitis. However, the absence of local side effects (section 4.3) provides a positive efficacy with other in-

#### 4.3 Budesonide

To date, the budesonide is essential (allergic) several studies intranasal budesonide in patients with perennial rhinitis (table IV). It has been found to be effective in patients with perennial rhinitis (Pipkorn and Berge, 1983). Intranasal budesonide is a potent anti-inflammatory agent, at least as effective as fluticasone propionate (Crant, 1982). A trial was well tolerated compared with a 1-week active treatment regarding growth.

In 91 patients, budesonide was significantly more effective than beclomethasone in reducing daily nasal discharge, pollen count, and pollen count response (1982) (fig. 1). A recent trial that differed from methasone when pollen count comparison was equally effective though the



ith non-allergic his study budesonide at 3 dosages to clear dose-response and there was no between any of spect to changes red rhinomanonately half the before treatment l by budesonide d only 2 patients finding was ob-rhinitis with as-n intranasal buduction in tissue 982). A previous rial noted budesonide vasomotor and re subdivided re-nide was only effective (Balle et al., 1980).

several long term trial rhinitis, but adverse reactions patients treated 1.2). In a recently (1983), 12 s received intral dosage was 400 sistently relieved no symptom re-he trial 3 patients to 200 $\mu$ g and no A 6-month open al rhinitis (in 38 ed that intranasal nificantly reduced or 2 and 6 months 3). Similarly, in a lts with perennial 60 to 400  $\mu$ g/day) n all nasal symp-

The conclusions from all these long term studies have been that intranasal budesonide is safe and effective in the treatment of perennial rhinitis. However, the open nature of these trials and the absence of long term comparative studies (see section 4.3) prevent a clear conclusion as to the relative efficacy of intranasal budesonide compared with other intranasal steroids in perennial rhinitis.

#### 4.3 Budesonide Compared with Other Drugs

To date, there have been no studies comparing budesonide with other drugs in patients with perennial (allergic or non-allergic) rhinitis. However, several studies have been reported comparing intranasal budesonide with alternative active treatments in patients with seasonal allergic rhinitis (table IV). In these trials intranasal budesonide was found to be as effective as intranasal flunisolide (Pipkorn and Geterud, 1984), more effective than intranasal sodium cromoglycate (unpublished trials on file, Astra) and the oral antihistamine dexchlorpheniramine maleate (Munch et al., 1983), and at least as effective as intranasal beclomethasone dipropionate (Pipkorn, 1983b; Pipkorn and Rundcrantz, 1982; Samuelsson, 1983). Generally, each trial was well-designed (single- or double-blind randomised comparisons in parallel groups of patients) with a 1-week run-in period followed by 3 weeks' active treatment, but little or no information regarding group comparability was presented.

In 91 patients sensitive to either birch or grass pollen, budesonide 200 $\mu$ g twice daily was significantly more effective in relieving nasal symptoms than beclomethasone dipropionate 100 $\mu$ g 4 times daily during the months of May and June, when pollen counts revealed high levels of birch and grass pollen, respectively (Pipkorn and Rundcrantz, 1982) [fig. 10]. Both in this study and in the more recent trial of Samuelsson (1983) it was concluded that differences between budesonide and beclomethasone dipropionate were more easily detected when pollen counts were high. In the only other comparison between these 2 agents, both seemed equally effective when administered twice daily, although the pollen levels during this trial were ex-




Fig. 10. Comparison between the effects of intranasal budesonide (200 $\mu$ g twice daily (▨)) and intranasal beclomethasone dipropionate (100 $\mu$ g 4 times daily (□)) on the mean symptom scores relative to baseline values, in 91 patients with seasonal allergic rhinitis. 64 patients were treated in May (31 with budesonide) and 27 in June (15 with budesonide) when there were high levels of birch pollen and grass pollen, respectively; \* significant difference between treatments (after Pipkorn and Rundcrantz, 1982).

Table IV. Summary of randomized short term (3-week) therapeutic trials in parallel groups of patients with seasonal allergic rhinitis comparing intranasal budesonide (200 µg bid) with alternative active treatments

Reference	No. of patients (budesonide group) <sup>a</sup>	Allergen (diagnosis)	Study design	Dosage of alternative therapy (route)	Results <sup>b</sup>					
					total nasal symptoms	nasal blockage	nasal sneezing	nasal itching	eye symptoms	patient preference
<i>Comparisons with decafluoromethane malate</i>										
Munch et al. (1983)	60 (31)	Birch pollen (history, st)	db	6mg bid (po)	BUD > DCP	BUD > OCP	BUD > DCP	BUD > DCP	BUD vs DCP <sup>c</sup>	BUD > DCP
<i>Comparison with fluticasone</i>										
Popkorn and Gatterud (1984)	58 (30)	Birch pollen (history, st) <sup>d</sup>	sb	100 µg bid (in)	BUD vs F	BUD vs F	BUD vs F	BUD vs F	BUD vs F	BUD > F
<i>Comparisons with beclomethasone dipropionate</i>										
Popkorn (1983e)	51 (26)	Birch pollen (history, st)	cb	200 µg bid (in)	BUD vs BDP	BUD vs BDP	BUD > BDP	BUD vs BDP	BUD vs BDP	BUD vs BDP
Popkorn and Runkelant (1982)	64 (31)	Birch pollen (history, st)	sb	100 µg qid (in)	BUD > BDP	BUD > BDP	BUD > BDP	BUD > BDP	BUD > BDP	BUD > BDP
Samuelsson (1983) <sup>f</sup>	27 (15)	Grass pollen (history, st)	sb	100 µg qid (in)	BUD > BDP	BUD > BDP	BUD > BDP	BUD vs BDP	BUD vs BDP	BUD > BDP
	41 (nd)	Birch pollen (history, st)	sb	200 µg bid (in)	BUD > BDP	BUD > BDP	BUD > BDP	BUD > BDP	BUD > BDP	BUD > BDP
<i>Comparisons with sodium cromoglycate</i>										
Unpublished trial	42 (21)	Grass pollen (history, st)	db	6.2mg 6x daily (in)	BUD > SCG	BUD > SCG	BUD > SCG	BUD > SCG	BUD > SCG	BUD > SCG
Unpublished trial <sup>g</sup>	42 (21)	Birch pollen (history, st, npt)	sb	6.2mg 6x daily (in)	BUD > SCG	BUD > SCG	BUD > SCG	BUD > SCG	BUD vs SCG	BUD > SCG

a Number of patients who completed the trial.

b BUD > signifies budesonide was significantly better; BUD > signifies a trend in favour of budesonide; BUD vs signifies that the 2 drugs produced equivalent results.

c Budesonide group used significantly more antihistamine - vasoconstrictor eye drops.

d Diagnosis was made by nasal provocation testing in 1 patient.

e Presented as a brief abstract with few details.

f Method of verification not stated.

g Treatment period in this study was 4 weeks.

Abbreviations: BUD = budesonide; DCP = decafluoromethane malate; F = fluticasone; BDP = beclomethasone dipropionate; SCG = sodium cromoglycate; cb = double-blind; sb = single-blind; st = skin tests; npt = nasal provocation tests; po = oral; in = intranasal; bid = twice daily; qid = 4 times daily; nd = no details of group sizes.

Th  
ide (4  
sal pu  
with p  
week  
nasal  
(Holo  
ently  
sympt  
rates.  
decre  
size an  
polyps.

e Presented as a brief abstract with few details.

f Method of verification not stated.

g Treatment period in this study was 4 weeks.

Abbreviations: BUD = budesonide; DCP = dexchlorpheniramine maleate; F = flunisolide; BOP = beclomethasone dipropionate; SCG = sodium cromoglycate; db = double-blind; sb = single-blind; et = skin tests; nat = nasal provocation tests; po = oral; in = intranasal; bid = twice daily; qid = 4 times daily; rd = no details of group sizes.

tremely low – approximately 15 times less than the previous season.

Pollen levels were quite high when intranasal budesonide and intranasal flunisolide were compared and both drugs appeared equally efficacious (Pipkorn and Geierud, 1984). Similarly, during a 4-week comparison with intranasal sodium cromoglycate (5.2mg 6 times daily) birch pollen levels were high and intranasal budesonide 200µg twice daily was significantly better in reducing nasal symptoms (unpublished trial on file, Astra). In this study there was no significant difference between the 2 treatment groups with respect to the severity of eye symptoms. Pollen counts were not performed during another comparison between intranasal budesonide (200µg twice daily) and intranasal sodium cromoglycate (5.2mg 5 times daily), and all symptom scores (including eye symptoms) were significantly lower for the budesonide group (unpublished trial on file, Astra). Finally, due to bad weather, pollen counts were extremely low when intranasal budesonide was compared with oral dexchlorpheniramine and this may explain why for a number of nasal symptoms only trends in favour of the intranasal corticosteroid were observed and not statistically significant advantages (Munch et al., 1983). These results clearly show the need to qualify the severity of allergen exposure when comparing drugs in patients with seasonal allergic rhinitis.

### 5. Treatment of Nasal Polyposis

The therapeutic efficacy of intranasal budesonide (400 µg/day) administered from an aqueous nasal pump spray in nasal polyposis was compared with placebo in a double-blind parallel group 16-week study in 19 patients with perennial intrinsic nasal symptoms associated with small nasal polyps (Holopainen et al., 1982). Budesonide was significantly more effective than placebo in reducing total symptom scores and increasing nasal peak flow rates. In addition, rhinoscopy revealed a distinct decrease in nasal congestion, a decrease in polyp size and a significant reduction in the number of polyps, all without evidence of drying and crusting,

for those patients treated with budesonide. While such findings are encouraging, since only 10 patients received active treatment in this study a larger controlled study is needed to clearly establish the place of budesonide in the treatment of nasal polyposis.

## 6. Side Effects

### 6.1 Inhaled Budesonide

In general terms, inhaled budesonide has been well-tolerated, with a high proportion of the published clinical trials to date reporting no adverse events associated with treatment. However, as previously emphasised (section 3), the majority of these studies in asthmatic patients have been of short term design (2 to 4 weeks) with only a small number of trials of greater than 4 weeks duration. Additional longer term clinical experience is needed to clearly establish the side effects profile of inhaled budesonide.

#### 6.1.1 Candidiasis, Dysphonia and Sore Throat

The most commonly reported adverse effects associated with the administration of inhaled budesonide have been oral candidiasis, dysphonia (hoarseness) and sore throat, as occurs with other inhaled corticosteroids (Srogden, 1983c). The relative incidence of oral candidiasis has varied widely, with some studies not finding any fungal growth (Willey et al., 1982) nor any increase in growth compared with baseline levels when each patient was receiving oral steroid therapy (Rosenhall et al., 1982a), while another reported a dose-response relationship between the total daily dose of budesonide inhaled without a spacer and the number of *Candida* colonies counted (Toogood et al., 1984a). In this latter study, budesonide inhaled without a spacer on a twice-daily basis, instead of 4 times daily, abolished the effect of increasing the daily dose of budesonide on candidiasis and almost eliminated the need for nystatin, but it was also associated with a small but significant deterioration of peak expiratory flow rate. The severity of dysphonia was also evaluated in this trial and was found to be infrequent at the start of the study and was unaffected by the daily dose or dose fre-

quency of inhaled budesonide. An earlier trial of comparable design revealed significantly less candidiasis when budesonide was inhaled with a spacer (50 or 750ml) compared with a conventional actuator, but there were no significant differences in the incidence of dysphonia among the 3 inhalers (Toogood et al., 1982c, 1984c). However, the level of dysphonia was minimal initially, so no firm conclusions should be drawn with respect to the effect of spacers on its relative incidence, although administration of beclomethasone dipropionate with a spacer has been shown to reduce dysphonia (Toogood et al., 1981). The changes observed for budesonide were independent of oral prednisone usage which has previously been implicated in increasing the risk of candidiasis when the drug is inhaled without a spacer.

### 6.1.2 Systemic Corticosteroid Withdrawal Effects

Of the long term trials published (section 3.2) only the studies of Adéiroth et al. (1984) and Rosenhall et al. (1982a) reported the incidence of adverse effects associated with high dose inhaled budesonide therapy. In the latter trial, 31 prednisolone-dependent asthmatics entered the study and inhaled budesonide was gradually substituted for the oral steroid. During the 1 year of follow-up, 11 patients had no adverse effects, 9 reported hoarseness or sore throat at least once (in 1 case it was severe enough to warrant withdrawal from the trial), 13 developed arthralgia or myalgia, 3 had exacerbation of eczema and 1 patient each developed pulmonary eosinophilia and sarcoidosis. In a continuation of this trial in 38 patients with chronic asthma, inhaled budesonide (200 to 1600 µg/day) was gradually substituted for oral prednisone and a similar level of adverse effects was recorded (Adéiroth et al., 1984). These side effects can all be explained in terms of a local reaction or the direct result of oral steroid withdrawal. This is similar to the findings with other inhaled corticosteroids where exacerbation of a previously controlled underlying disease has been reported following substitution of oral with inhaled steroid (Brogden, 1983c).

### 6.1.3 Adrenal Suppression

As noted previously (section 1.3), inhaled doses of budesonide (up to 800 µg/day) are not normally associated with significant reductions in plasma cortisol concentrations, and substitution of inhaled budesonide for oral prednisolone has generally resulted in a gradual improvement in plasma cortisol levels. However, in a recently reported 6-week trial in 28 chronic asthmatics who were poorly controlled with normal inhaled doses of beclomethasone dipropionate (mean 883 µg/day), high inhaled dosages of budesonide (1600 µg/day) or beclomethasone dipropionate (1500 µg/day) were of benefit to the majority of patients but they also caused some adrenal suppression (Ehden and Davies, 1984). This resulted in lower morning plasma cortisol levels compared with baseline values, but neither corticosteroid had any significant effect on the cortisol response to tetracosactrin stimulation. To date, the stimulatory response to tetracosactrin has been the most widely used test in both adult and child asthmatics receiving usual doses of budesonide, and no abnormal results have been noted (section 1.3). Since recovery of HPA function after long term oral corticosteroid therapy may take up to a year, it is essential to take special care during this period, if inhaled budesonide is to be substituted, so as to enable the patient to cope with stressful situations such as trauma, surgery, severe infections or an acute attack of asthma.

### 6.1.4 Laboratory Data and Miscellaneous Side Effects

During a 12-month trial with budesonide 160 µg 4 times daily only 10 patients of 166 withdrew from the trial for drug-related reasons (unpublished data on file, Astra). The majority of these were related to adverse local reactions and two were due to depression. Most laboratory parameters were not significantly changed during follow-up although alkaline phosphatase was significantly increased, and leucocyte count and serum bilirubin were slightly but significantly decreased - these changes were of doubtful clinical relevance.

An isolated case of severe bronchoconstriction induced by a single puff (200 µg) of inhaled budo-

sonide has been reported (Lane, 1984). bronchoconstrictor propellants, but can occur. Another case of budesonide in a child have been reported. behaviour in secondary school. Cocaine, a stimulant, is used, especially steroids, and appeared with course of evaluation agent of for ethical and possible that the provoked the

### 6.2 Intermittent

The most commonly associated with budesonide in patients with asthma have been throat irritation.

In short term trials with seasonal asthma budesonide seemed to histamine dose of the mouth, significantly reduced fluticasone (1 similar incidence). beclomethasone, Pipakorn and cromoglycate in longer term trials, the incidence (1982; Lindqvist, 1983) and were measured range. In 2 of reported were in 1 patient an

ion 1.3), inhaled doses (day) are not normally reductions in plasma substitution of inhaled alone has generally resistant in plasma cortisol / reported 6-week trial ho were poorly condoses of beclometha- $\mu\text{g/day}$ ), high inhaled  $1\ \mu\text{g/day}$  or beclome- $\text{g/day}$  were of benefit but they also caused (Ebdon and Davies, morning plasma cor-seline values, but nei-gnificant effect on the trin stimulation. To to tetracosactrin has st in both adult and al doses of budeson-ave been noted (sec-A function after long py may take up to a cial care during this is to be substituted, cope with stressful rgergy, severe infec-thma.

#### Miscellaneous

h budesonide  $100\ \mu\text{g}$  f 16% withdrew from is (unpublished data f these were related d two were due to arameters were not flow-up although al-antly increased, and irubin were slightly ese changes were of

ronchoconstriction g) of inhaled bude-

sonide has been reported (McGivern and Macfar-lane, 1984). Challenge tests revealed appreciable bronchoconstriction to both budesonide and its propellants, but contaminants (from the alumin-ium can or rubber valve) may also be implicated. Another case report indicated that inhaled bude-sonide in a dose of two  $50\ \mu\text{g}$  puffs twice daily may have been responsible for an episode of psychotic behaviour in a 5½-year-old girl being treated for secondary bronchial hyperactivity (Lewis and Cochrane, 1983). Steroid psychosis is well recog-nised, especially in patients on high dose systemic steroids, and in this instance the symptoms dis-appeared when the dosage was halved. The time course of events suggests budesonide was the caus-ative agent although no rechallenge was performed for ethical and parental reasons and it remains pos-sible that the propellants in the inhaler may have provoked the reaction.

#### 6.2 Intranasal Budesonide

The most frequently reported adverse effects as-sociated with the intranasal application of bude-sonide in patients with allergic or non-allergic rhin-itis have been local reactions such as nasal stinging, throat irritation, dry nose and nasal bleeding.

In short term comparative studies in patients with seasonal allergic rhinitis, intranasal budeson-ide seemed to cause fewer side effects than the anti-histamine dechlorpheniramine (especially dryness of the mouth, and drowsiness) (Munch et al., 1983), significantly less ( $p < 0.02$ ) nasal irritation than flunisolide (Pipkorn and Ceterud, 1984), and a similar incidence of minor transient reactions as beclomethasone dipropionate (Pipkorn, 1983b; Pipkorn and Runderantz, 1982) and sodium cromoglycate (unpublished trials on file, Astra). In longer term trials in patients with perennial rhin-itis, the incidence of side effects has been low (Balle, 1982; Lindqvist et al., 1982, 1983; Pipkorn and Berge, 1983) and those laboratory parameters which were measured all remained within the reference range. In 2 of these studies the only adverse effects reported were a transient skin rash around the nose in 1 patient and nasal bleeding in 4 patients (Balle,

1982; Pipkorn and Berge, 1983). In all 4 studies, ad-renal function remained normal as assessed by basal plasma cortisol concentrations and their re-sponse to tetracosactrin stimulation. In a 4-month placebo-controlled double-blind trial in 19 patients with nasal polyposis, intranasal budesonide pro-duced a low incidence of mild transient side effects with no evidence of mucosal drying or crusting (Holopainen et al., 1982).

### 7. Dosage and Administration

#### 7.1 Asthma

The recommended inhaled dosage of budeson-ide for the treatment of bronchial asthma in adults is individual. Initially it is normally 400 to 1600  $\mu\text{g/day}$  divided into 2 or 4 administrations. The maintenance dose is also individual and should be the lowest dose which leaves the patient symptom free. In adults this is usually achieved with a dose of 200 to 400  $\mu\text{g}$  twice daily. In children with asthma the recommended regimen is 200 to 400  $\mu\text{g/day}$ , divided into 2 or 4 administrations. There is evi-dence that a twice daily regimen may be less ef-fective than 4 times daily administration when asthma is poorly controlled. As for all aerosolised corticosteroids it is important that the patient uses the inhaler correctly, since failure to respond has been correlated with poor technique (Newman, 1983). Inhalation through a spacer may prove to be clinically useful for a proportion of patients by augmenting the airways response and reducing the severity of candidiasis for any particular dose of budesonide. Special care should be observed in patients with pulmonary tuberculosis, fungal and viral infections of the airways, those transferring from systemic steroids, and in pregnancy.

#### 7.2 Rhinitis

In the treatment of seasonal and perennial al-lergic rhinitis and vasomotor rhinitis the recom-mended budesonide dosage is 2 applications into each nostril morning and evening from a metered-dose aerosol delivering  $50\ \mu\text{g}$  per actuation ( $400\ \mu\text{g/day}$ ). When a good response has been achieved the

The results from studies conducted to date indicate that budesonide is an effective topical corticosteroid for the clinical management of asthma and rhinitis. However, as would be expected at this stage in its development, the extent of published therapeutic experience is limited, especially when compared with that of beclomethasone dipropionate – the most widely studied topical agent in these conditions.

term published trials. In a single study of 19 patients with nasal polyposis, intranasal budesonide was significantly better than placebo in reducing the size and number of polyps and in relieving nasal symptoms.

Thus, budesonide appears to offer a safe and effective alternative in conditions where an inhaled or intranasal corticosteroid is indicated. However, its relative efficacy and tolerability compared with other corticosteroids needs further clarification in longer term studies.

Adcroft, E., Rosenhaft, L. and Glennow, C.: High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics - a two year study (In press, 1984).

Aherne, G.W., Littleton, P., Thälén, A. and Marks, V.: A sensitive radioimmunoassay for budesonide in plasma. *Journal of Steroid Biochemistry* 17: 559-565 (1982).

Andersson, P.: Effects of inhibitors of anaphylactic mediators in two models of bronchial anaphylaxis in anaesthetized guinea-pigs. *British Journal of Pharmacology* 77: 501-507 (1982).

Andersson, P. and Brattsand, R.: Protective effects of the glucocorticoid, budesonide, on lung anaphylaxis in actively sensitized guinea-pigs. Inhibition of IgE but not of IgG-mediated anaphylaxis. *British Journal of Pharmacology* 76: 139-147 (1982).

Andersson, P., Brattsand, R., Bränge, C., Källström, L. and Ståhle, G.: Effect of budesonide and beclomethasone dipropionate on antigen-induced bronchial anaphylaxis and plasma cortisol in guinea-pigs. Abstract submitted to the XII Congress of the European Academy of Allergy and Clinical Immunology, Rome (1983).

Andersson, P., Brattsand, R., Edsbacker, S., Källström, L. and Ryrfeldt, A.: Biotransformation rate (*in vitro*) and systemic potency (*in vivo*) of the topical glucocorticoid budesonide in male and female rats. *Journal of Steroid Biochemistry* 17: 703-706 (1982a).

Andersson, P., Chignard, M., Le Couedic, J.-P., Bränge, C., Nilsson, T. and Juhlin, M.: Effect of glucocorticosteroid (GCS) treatment on antigen-induced mediator release from sensitized guinea-pig lungs. Abstract submitted to the 3rd Congress of the European Society of Rheumatology (1984).

Andersson, P., Edsbacker, S., Ryrfeldt, A. and von Fahr, C.: *In vitro* biotransformation of glucocorticoids in liver and skin homogenate fraction from man, rat and hairless mouse. *Journal of Steroid Biochemistry* 16: 757-775 (1982b).

Balle, V.H.: The effect of budesonide in perianal rhinitis. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127-204 (1982).

Balle, V.H., Pedersen, U. and Engby, B.: Allergic perianal and non-allergic, vasomotor rhinitis treated with budesonide na-

ed spray. *Klin.  
Wochenschr.*,  
Hendel, M.: Local  
glucocorticoid  
measured by  
(1983).  
Bergstrand, U.:  
Brattstad, R.,  
Leflund, C.,  
Löfdahl, B.:  
217-230 (1979).  
Pernstén, L.L.C.:  
of triamcinolone  
(1982).  
Björkander, J.E.:  
Methodologi-  
steroids: Re-  
aerosols in a  
primary care  
Grönvall, K. A.,  
and of Fluticasone,  
ically applied  
37 (1987).  
Brattstad, R.:  
Thomsson, S.:  
ing and re-  
(Suppl. 122).  
Brattstad, R.,  
back, M.: Immu-  
nation and  
inflammatory  
secretion in the  
meeting of the  
Brattstad, R.,  
stad, E.: Neu-  
topical and en-  
cology 77: 4  
Brattstad, R.,  
stad, E.: Inflam-  
nucleus facies  
of glucocorti-  
755 (1982c).  
Brattstad, R.,  
stad, E.: Does  
high ratio be-  
*Journal of Rheumatism*  
Bradley, A.B.M.:  
of beclomethasone  
challenge in asth-  
*Journal of Allergy*  
British Thoracic Society:  
steroids con-  
long term ef-  
473 (1975).  
Roggen, R.N.:

dy of 19 patients  
budesonide was  
educing the size  
ing nasal symp-

for a safe and  
here an inhaled  
ated. However,  
compared with  
clarification in

High dose inhaled  
id-dependent asth-

ks. V.: A sensitive  
a. Journal of Ster-

etic mediators in  
sthetized guinea-  
01-307 (1982).  
ffects of the glu-  
s in actively sen-  
of IgG-mediated  
ogy 76: 139-147

n. L. and Stahre.  
dipropionate on  
asma cortisol in  
Congress of the  
al Immunology.

llström, L. and  
) and systemic  
budesonide in  
mistry 17: 703-

range, C.: Nils-  
steroid (GCS)  
to from sensi-  
3rd Congress  
86.

n Bahr, C.: In  
liver and the  
vrouse. Jour-  
b).

rhinitis. Euro-  
pl. 122): 193-

terennial and  
desonide na-

sal spray. *Rhinology* 18: 135-142 (1980).

Barn, D.: Budesonide in asthma (submitted for publication, 1984).

Bende, M., Lindqvist, N. and Pipkorn, U.: Effect of a topical glucocorticoid, budesonide, on nasal mucosal blood flow as measured with  $^{133}\text{Xe}$  wash-out technique. *Allergy* 39: 451-464 (1983).

Bergstrand, H., Björnsson, A., Lundquist, B., Nilsson, A. and Brattsand, R.: Inhibitory effect of glucocorticosteroids on anti-IgE-induced histamine release from human basophilic leukocytes: Evidence for a dual mechanism of action. *Allergy* 39: 217-230 (1984).

Bernstein, I.L., Chervinsky, P. and Felliars, C.J.: Efficacy and safety of triamcinolone aerosol in chronic asthma. *Chest* 81: 20-26 (1982).

Björkander, J., Forngren, H., Johansson, S.A. and Millqvist, E.: Methodological aspects on clinical trials with inhaled corticosteroids: Results of two comparisons between two steroid aerosols in patients with asthma. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 108-117 (1982).

Brattsand, R. and Kallström, L.: Importance of the skin barrier and of liver biotransformation on the systemic activity of topically applied budesonide. *Acta Pharmaceutica Suecica* 20: 36-37 (1983).

Brattsand, R., Kallström, L., Nilsson, E., Ryrfield, A. and Tonnesson, M.: The lung disposition of budesonide in guinea pig and rat. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 263-265 (1982a).

Brattsand, R., Kallström, L., Wieslander, P., Andersson, P., Dahlback, M. and Dahl, R.: A model for particle-induced inflammation and edema formation in the rat lung and the anti-inflammatory action of the glucocorticosteroid (GCS) budesonide in this model. Abstract submitted to the Edinburgh meeting of the European Society of Pneumology (1983).

Brattsand, R., Thälén, A., Roempke, K., Kallström, L. and Gruvstad, E.: New glucocorticoids with improved ratio between topical and systemic activities. *British Journal of Pharmacology* 77: 433P (1982b).

Brattsand, R., Thälén, A., Roempke, K., Kallström, L. and Gruvstad, E.: Influence of 16 $\alpha$ , 17 $\alpha$ -acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. *Journal of Steroid Biochemistry* 16: 779-786 (1982c).

Brattsand, R., Thälén, A., Roempke, K., Kallström, L. and Gruvstad, E.: Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 62-73 (1982d).

Broslin, A.B.N., Pepys, J., Davies, R.J. and Hendrick, D.J.: Effect of beclomethasone dipropionate on antigen bronchial challenge in asthmatic patients. *Australian and New Zealand Journal of Medicine* 3: 324 (1973).

British Thoracic and Tuberculosis Association: Inhaled corticosteroids compared with oral prednisone in patients starting long term corticosteroid therapy for asthma. *Lancet* 2: 469-473 (1975).

Brogden, R.N.: Inhaled steroids: Pharmacology and toxicology;

in Clark (Ed.) *Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy*. pp. 121-134 (ADIS Press, Auckland 1983a).

Brogden, R.N.: Inhaled steroids: Studies in adult and childhood asthma; in Clark (Ed.) *Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy*. pp. 135-153 (ADIS Press, Auckland 1983b).

Brogden, R.N.: Factors which may affect the response to inhaled steroids; side effects; in Clark (Ed.) *Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy*. pp. 154-165 (ADIS Press, Auckland 1983c).

Brogden, R.N., Heel, R.C., Speight, T.M. and Avery, G.S.: Beclomethasone dipropionate: A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. *Drugs* 28: 99-126 (1984).

Burge, P.S.: The effects of corticosteroids on the immediate asthmatic reaction. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 163-166 (1982).

Cameron, A.W., Stanley, I.M. and Wright, H.J.: Randomised double blind controlled clinical trial of intranasal budesonide in treatment of hay fever. *British Medical Journal* 288: 1821-1864 (1984).

Chiang, J.L., Patterson, R., McGillen, J.J., Phair, J.P., Roberts, M., Harris, K.E. and Riesing, K.S.: Long term corticosteroid effect on lymphocyte and polymorphonuclear cell function in asthmatics. *Journal of Allergy and Clinical Immunology* 65: 253-258 (1980).

Cochrane, G.M.: Systemic steroids in asthma; in Clark (Ed.) *Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy*. pp. 103-120 (ADIS Press, Auckland 1983).

Dahl, R. and Johansson, S.-Å.: Clinical effect of bid and tid administration of inhaled budesonide. A double-blind controlled study. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 268-269 (1982a).

Dahl, R. and Johansson, S.-Å.: Effect of inhaled budesonide on dual asthmatic reactions. *Allergy* 37 (Suppl. 1): 19 (1982b).

Dahl, R. and Johansson, S.-Å.: Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 167-175 (1982c).

Dahl, R. and Johansson, S.-Å.: Effect on lung function of budesonide by inhalation, terbutaline s.d. and placebo given simultaneously or as single treatments. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 132-137 (1982d).

Dahlberg, E., Thälén, A., Brattsand, R., Gustafsson, L.-Å., Johansson, U., Roempke, K. and Sörsten, T.: Correlation between chemical structure, receptor binding and biological activity of some novel, high active, 16 $\alpha$ , 17 $\alpha$ -acetal-substituted glucocorticoids. *Molecular Pharmacology* 25: 70-78 (1984).

Elden, P. and Davies, B.H.: High-dose corticosteroid inhalers for asthma. *Lancet* 2: 576 (1984).

Edsbacker, S., Jonsson, S., Lindberg, C., Ryrfield, A. and Thälén, A.: Metabolic pathways of the topical glucocorticoid budesonide in man. *Drug Metabolism and Disposition* 11: 590-596 (1983).

- Ellul-Micallef, R., Hansson, E. and Johansson, S.-Å.: Budesonide: A new corticosteroid in bronchial asthma. *European Journal of Respiratory Diseases* 61: 167-173 (1980).
- Ellul-Micallef, R. and Johansson, S.-Å.: Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. *British Journal of Clinical Pharmacology* 15: 419-422 (1983a).
- Ellul-Micallef, R. and Johansson, S.-Å.: Dose-frequency in chronic bronchial asthma with a new corticosteroid budesonide; in Johansson, S.-Å. (Ed.) *Evaluation of Budesonide - a new glucocorticosteroid for local treatment of asthma* (University of Lund, 1983b).
- Field, H.V., Jenkinson, P.M.A., Frame, M.H. and Warner, J.O.: Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler. *Archives of Disease in Childhood* 57: 864-866 (1982).
- Forsberg, K., Rysfeldt, A. and Sorenby, L.: Protective effects of budesonide on lung anaphylaxis in actively sensitized guinea pigs: Inhibition of IgG-mediated anaphylaxis. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 257-259 (1982).
- Forsberg, K. and Sorenby, L.: The influence of a new corticosteroid, budesonide, on anaphylactic bronchoconstriction and SRS-A release in the guinea pig. *Agents and Actions* 11: 391-395 (1981).
- Gruvstad, E. and Bengtsson, B.: A comparison of a new steroid, budesonide, with other topical corticosteroids in the vasoconstriction assay. *Drugs Under Experimental and Clinical Research* 6: 255-260 (1980).
- Hartley, J.P., Charles, T.J. and Seaton, A.: Betamethasone valerate inhalation and exercise-induced asthma in adults. *British Journal of Diseases of the Chest* 71: 253-258 (1977).
- Henriksen, J.M.: Effects of budesonide inhalation therapy on exercise-induced asthma in children (Submitted for publication, 1984).
- Henriksen, J.M. and Dahl, R.: Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. *American Review of Respiratory Disease* 128: 993-997 (1983).
- Henriksen, J.M. and Wenzel, A.: Effect of intranasal corticosteroid (Budesonide) on children with asthma and perennial rhinitis. *Folia Allergologica et Immunologica Clinica* 30 (Suppl. 4): 29 (1983).
- Hodgson, S.V., McPherson, A. and Friedman, M.: The effect of betamethasone valerate aerosol on exercise-induced asthma in children. *Postgraduate Medical Journal* 50 (Suppl. 4): 69-72 (1974).
- Holopainen, E., Grahne, B., Malmberg, H., Makinen, J. and Lindqvist, N.: Budesonide in the treatment of nasal polypsis. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 221-228 (1982).
- Johansson, S.-Å., Andersson, K.-E., Brattsand, R., Gruvstad, E. and Hedner, P.: Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. *European Academy of Allergy and Clinical Immunology* 2: 709-715 (1982a).
- Johansson, S.-Å., Andersson, K.-E., Brattsand, R., Gruvstad, E. and Hedner, P.: Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 74-82 (1982b).
- Johansson, S.-Å., Andersson, K.-E., Brattsand, R., Gruvstad, E. and Hedner, P.: Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. *European Journal of Clinical Pharmacology* 22: 523-529 (1982c).
- Johansson, S.-Å. and Dahl, R.: A double-blind dose response study of budesonide by inhalation in patients with bronchial asthma (submitted for publication, 1984).
- Kay, A.B.: The immunological basis of asthma; in Clark (Ed.) *Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy*, pp. 46-60 (ADIS Press, Auckland 1983).
- Kjellman, M., Moller, C., Glennow, C. and Konar, A.: A comparison of Becotide<sup>®</sup> and budesonide in children. *European Journal of Respiratory Diseases* 63 (Suppl. 124): 127 (1982).
- Laursen, L.C., Tandorf, E., Weeke, B. and Glennow, C.: High-dose inhaled budesonide in treatment of severe steroid-dependent asthmatics. *Lancet* 2: 1305 (1983).
- Lewis, L.D. and Cochran, G.M.: Psychosis in a child inhaling budesonide. *Lancet* 2: 634 (1983).
- Lindqvist, N., Balle, V., Karma, P., Narja, J., Lindstrom, D., Makinen, J., Pipkorn, U., Pukander, J., Suonpaa, J. and Ostlund, W.: A 12-month open tolerance study with budesonide nasal aerosol in perennial rhinitis. A multicentre study. *Fifth Asia-Oceania Congress of Otorhinolaryngological Societies* (Korea), p. 335 (1983).
- Lindqvist, N., Balle, V., Karma, P., Lindstrom, D., Pipkorn, U., Suonpaa, J. and Ostlund, W.: Six-month open tolerance study with budesonide nasal aerosol in patients suffering from perennial rhinitis. A multicentre trial. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 270-271 (1982).
- Lofdahl, C.-G., Mellstrand, T. and Svedmyr, N.: Glucocorticoids and asthma. Studies of resistance and systemic effects of glucocorticoids. *European Journal of Respiratory Diseases* 63 (Suppl. 136): 69-79 (1984).
- Malm, L., Wihl, J.A., Lamm, C.J. and Lindqvist, N.: Reduction of metacholine-induced nasal secretion by treatment with a new topical steroid in perennial non-allergic rhinitis. *Allergy* 36: 209-214 (1981).
- McGovern, D.V. and Macfarlane, J.: Severe bronchoconstriction after inhalation of budesonide. *British Medical Journal* 388: 447 (1984).
- Moren, F. and Andersson, J.: Fraction of dose exhaled after administration of pressurized inhalation aerosols. *International Journal of Pharmaceutics* 6: 295-300 (1980).
- Munch, E.P., Selberg, M., Norzellet, T.T. and Mejdind, N.: A comparative study of dexchlorpheniramine maleate sustained release tablets and budesonide nasal spray in seasonal allergic rhinitis. *Allergy* 38: 517-524 (1983).
- Munch, E.P., Weck, B. and Johansson, S.-Å.: The effect of bu-

desonide  
rhinitis  
pean  
184  
Newman  
in Ast  
pp. 2  
Newman  
Depo  
exten  
12: 2  
Norman  
oid (1  
while  
Clinic  
Nyholm  
vaning  
of the  
Europ  
Pelikan  
cromo  
media  
Annal  
Pepys, J.  
Hutch  
pionate  
actions  
Pipkorn, U.  
man, A  
Pipkorn, U.  
37: 359  
Pipkorn, U.  
to aller  
Journal  
(1982c)  
Pipkorn, U.  
mucosa  
(1983a)  
Pipkorn, U.  
methase  
Rhinitis  
Pipkorn, U.  
histamine  
lery 37:  
Pipkorn, U.  
of vapor  
(1983)  
Pipkorn, U.  
sonide as  
allergic r  
Pipkorn, U.  
sone die  
Eumnea  
211-220  
Pipkorn, U.



Brattsand, R.; Gruvstad, E. Systemic glucocorticoid potentiation of budesonide and prednisone dipropionate and prednisone dipropionate in man. *Journal of Respiratory Diseases* 63 (Suppl. 122): 175-184 (1982).

Brattsand, R.; Gruvstad, E. Systemic glucocorticoid potentiation of budesonide in man. *Pharmacology* 22: 523-529 (1982).

A blind dose response study in patients with bronchial asthma

of asthma: in Clark (Ed.) *In the Light of Inhalation* (Auckland 1983).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. High-dose response of severe steroid-dependent asthma in a child inhaling budesonide. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 128 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

Clark, R. and Konar, A. A comparative study with budesonide and prednisone. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 127 (1982).

new nasal steroid. *Rhinology* 18: 171-175 (1980).

Rosenhall, L.; Adelroth, E. and Johansson, S.-A.: One year treatment with high doses of a new steroid aerosol (budesonide) in steroid dependent asthmatic patients. *European Academy of Allergy and Clinical Immunology* 2: 777-783 (1982a).

Rosenhall, L.; Lundqvist, G.; Adelroth, E. and Glennow, C.: Comparison between inhaled and oral corticosteroids in patients with chronic asthma. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 154-162 (1982b).

Roth, G.; Wikby, A.; Nilsson, L. and Thälén, A.: High-performance liquid chromatographic determination of epinephrine, isoprenaline and content of the glucocorticoid budesonide and preparation of primary standard. *Journal of Pharmaceutical Sciences* 69: 766-770 (1980).

Ryrfeldt, A.; Andersson, P.; Edsbacker, S.; Tonnesson, M.; Davies, D. and Pauwels, R.: Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 86-95 (1982).

Ryrfeldt, A.; Edsbacker, S. and Pauwels, R.: Kinetics of the epinephrine glucocorticoid budesonide. *Clinical Pharmacology and Therapeutics* 35: 525-530 (1984).

Ryrfeldt, A.; Tonnesson, M.; Nilsson, F. and Wikby, A.: Pharmacokinetic studies of a potent glucocorticoid (budesonide) in dogs by high-performance liquid chromatography. *Journal of Steroid Biochemistry* 10: 317-324 (1979).

Saavedra-Delgado, A.M.P.; Mathew, K.P.; Pan, P.M.; Kay, D.H. and Milkenberg, M.L.: Dose-response studies of the suppression of whole blood histamine and basophil counts by prednisone. *Journal of Allergy and Clinical Immunology* 66: 154-171 (1980).

Samuelsson, A.: A comparison between budesonide and beclomethasone-dipropionate in patients with birch-pollen induced hay fever. *Folia Allergologica et Immunologica Clinica* 30 (Suppl. 4): 102 (1983).

Springer, D.L.; Bloom, F.L.; Brestel, E.P. and Wittig, H.J.: One year trial of aerosolized flunisolide in severe steroid-dependent asthmatics. (Abstract No. 186.) *Annals of Allergy* 59: 70 (1987).

Steenen, H. and Lundqvist, N.: Treatment of grass pollen-induced hay fever with intranasal budesonide. *Allergy* 36: 245-249 (1981).

Stiksa, G.; Glennow, C. and Johansson, N.: An open cross-over trial with budesonide and beclomethasone dipropionate in patients with bronchial asthma. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 266-267 (1982).

Svensjö, E. and Reemtsma, K.: Time dependent inhibition of bradykinin induced mucovascular permeability increase by local glucocorticoid treatment. Abstract submitted to the 3rd Congress of the European Society of Rheumatology (1984).

Thälén, A. and Brattsand, R.: Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. *Arzneimittel-Forschung* 29: 1687-1690 (1979).

Thälén, A.; Brattsand, R. and Gruvstad, E.: Synthesis and pharmacological properties of some 16 $\alpha$ , 17 $\alpha$  acetals of 16 $\alpha$ -hydroxybudesonide, 16 $\alpha$ -hydroxyprednisolone and fluticasone.

- inated 16 $\alpha$ -hydroxyprednisolones. *Acta Pharmaceutica Suecica* 21: 109-124 (1984).
- Tivenius, L., Kivlong, J. and Glennow, C.: The effect of budesonide on bronchial provocation after varying lengths of pre-treatment. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 126 (1982).
- Toogood, J.H.: Steroids in asthma. *Lancet* 2: 1185 (1979).
- Toogood, J.H.: Concentrated aerosol formulations in asthma. *Lancet* 2: 790-791 (1983).
- Toogood, J., Baskerville, J., Jennings, B. and Johansson, S.-Å.: Inhaled budesonide (B) vs. daily oral prednisone (P) for preventing asthma relapses in unstable asthmatics. Abstract submitted to the Scientific Program, American College of Chest Physicians and International Academy of Chest Physicians and Surgeons, Portugal (1984d).
- Toogood, J., Baskerville, J.C., Jennings, B., Johansson, S.-Å. and Lefcoe, N.: Influence of dose-frequency and periodicity on response to aerosol steroids (AS) in asthma. *Journal of Allergy and Clinical Immunology* 69: 139 (1982a).
- Toogood, J.H., Baskerville, J.C., Jennings, B., Lefcoe, N.M. and Johansson, S.-Å.: Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. *Journal of Allergy and Clinical Immunology* 70: 286-298 (1982b).
- Toogood, J.H., Baskerville, J., Jennings, B., Lefcoe, N.M. and Johansson, S.-Å.: Use of spacers to facilitate inhaled corticosteroid treatment of asthma. *American Review of Respiratory Diseases* 129: 773-779 (1984e).
- Toogood, J.H., Jennings, B., Baskerville, J., Anderson, J. and Johansson, S.-Å.: Dosing regimen of budesonide and occurrence of oropharyngeal complications. *European Journal of Respiratory Diseases* 65: 35-44 (1984c).
- Toogood, J.H., Jennings, B., Baskerville, J. and Johansson, S.-Å.: Clinical use of spacer systems for corticosteroid inhalation therapy: A preliminary analysis. *European Journal of Respiratory Diseases* 63 (Suppl. 122): 100-107 (1982e).
- Toogood, J.H., Jennings, B., Baskerville, J. and Johansson, S.-Å.: Which asthmatic patients respond best to a spacer (Sp)? *Journal of Allergy and Clinical Immunology* 73 (Suppl.): 121 (1984b).
- Toogood, J.H., Jennings, B., Baskerville, J., Lefcoe, N. and Johansson, S.-Å.: Comparison of alternate-morning prednisone vs. inhaled steroid (B) for asthma. *Annals of the Royal College of Physicians and Surgeons of Canada* 16: 308 (1983).
- Toogood, J.H., Jennings, B., Baskerville, J., Lefcoe, N. and Newhouse, M.: Assessment of a device for reducing oropharyngeal complications during bclomethasone treatment of asthma. *American Review of Respiratory Diseases* 123: 113 (1981).
- Wilsvik, J.S., Jensen, A.O. and Wahlstad, R.: The effect of bclomethasone dipropionate aerosol on allergen-induced nasal stenosis. *Clinical Allergy* 5: 291-294 (1975).
- Wotland, A., Møller, P. and Lindqvist, N.: Budesonide - a new steroid for intranasal use. A double-blind clinical comparison between budesonide and placebo in patients with seasonal allergic rhinitis. *Allergy* 35: 425-428 (1981).
- Webb, J.: Some tests of pituitary adrenal function and their application to the management of steroid-treated asthmatic patients; in Clark (Ed.) *Steroids in Asthma: A Reappraisal in the Light of Inhalation Therapy*, pp. 227-233 (ADIS Press, Auckland 1983).
- Wenzel, A., Henriksen, J. and Melsen, B.: Nasal respiratory resistance and head posture: Effect of intranasal corticosteroid (Budesonide) in children with asthma and perennial rhinitis. *American Journal of Orthodontics* 84: 422-426 (1983).
- Wikby, A., Thälén, A. and Öresten, G.: Separation of epimers of budesonide and related corticosteroids by high-performance liquid chromatography: A comparison between straight- and reversed-phase systems. *Journal of Chromatography* 157: 65-74 (1978).
- Willey, R.F., Godden, D.J., Carmichael, J., Preston, P., Frame, M. and Crompton, G.K.: Comparison of twice daily administration of new corticosteroid budesonide with bclomethasone dipropionate four times daily in the treatment of chronic asthma. *British Journal of Diseases of the Chest* 76: 61-63 (1982).
- Wyatt, R., Waschek, J., Weinberger, M. and Sherman, B.: Effects of inhaled bclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma. *New England Journal of Medicine* 299: 1387 (1978).

Authors' address: Stephen P. Chakel, ADIS Drug Information Services, P.O. Box 34-030, Birkenhead, Auckland 10 (New Zealand).

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.